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ABSTRACT
Polycyclic aromatic hydrocarbons (PAHs) are common environmental pollutants
resulting from incomplete combustion of organic matter, emission sources, automobile
exhausts, cigarette smoke (CS), residential wood, or coal combustion. PAHs are readily
absorbed from the gastrointestinal tract of mammals and have toxic, mutagenic and/or
carcinogenic consequences. More than 100 different PAH compounds are identified.
Sixteen of the common PAHs typically analyzed have been listed by the Environmental
Protection Agency (EPA) among 129 priority pollutants, and five of which are listed
among the 25 hazardous substances that are believed to have the most potential threat to
human health at priority superfund sites.
CS has been implicated as a major risk factor in atherosclerotic heart disease
through a mechanism that involves endothelial cell (EC) injury and apoptosis or
programmed cell death. Little is known about the specific components of CS responsible
for this effect or the mechanisms by which CS induces EC injury and progression of
atherosclerosis. However, the phospholipase A2/arachidonic acid (PLA2/AA) pathway
might be involved in SC-induced EC injury.
In this research, the long-range goal was to understand the role of several P AHs
found in the environment and CS in the EC and smooth muscle cells (SMC) injury. The
hypothesis to be tested is that EC and SMC PAR-induced apoptosis is mediated by
PLAi/AA pathway.
The objectives of this research were 1) to evaluate the effects on EC injury of
different PAHs present in high concentration in both Chattanooga creek and CS. 2) to
test the molecular mechanisms by which PAHs induce such effect. 3) to test the effect of
IV

PAHs on SMC in vitro and to characterize the role ofdifferent PLA2 isoforms in such
effect.
In this research, we found that Chattanooga creek contains extremely high levels
of11 out of16 EPA priority PAHs. The levels range from 10,625 mg/kg soil
(phenanthrene) to 97 mg/kg soil for fluorene compounds. Six out of the 11 compounds
studied, found in the creek or in CS, activate the AA cascade and induce apoptosis ofEC.
Three of the 11 PAHs cause these effects by activating and increasing the expression of
two different isoforms ofPLA2 ; the Group VI� and the Group IVy enzymes.
Furthermore, three out of 11 activate and increase expression of only the Group IVy
PLA2. PLA2 activation and release ofAA is associated with an increase in apoptosis as
measured by histone fragmentation and cleavage ofPARP. From these results, we
hypothesize that the water solubility as well as the molecular structures of the compounds
play important roles in the effects ofP AHs on EC PLA2 activation and apoptosis. These
data suggest that small molecular weight, highly water soluble compounds present in
high concentrations in the Chattanooga creek and CS may be potentially toxic confirming
the need for further studies.
We also found that 8 PAHs present in high concentrations in CS and in urban
pollution induce EC apoptosis by a mechanism that involves PLA2-mediated activation of
JNK.s, p-38, and caspases-8, -9, and -3. PAHs induce phosphorylation of JNK-1, JNK-2,
p-38, and the transcription factor c-Jun, resulting in apoptosis in EC. This effect is
inhibited significantly by MAPP (Group IV and VI PLA2 inhibitor) and JNK-1 L form
(JNK-1 and -2 inhibitor) but not with SB203580 (p-38 inhibitor). These data provide
compelling evidence that PAHs induce apoptosis by a mechanism that involves fatty
V

acid-induced phosphorylation of JNK-1 and JNK-2. Furthermore, p-38 phosphorylation
did not participate in the mechanism by which PAHs induce apoptosis. This study also
establishes a link between the discrete structure of these PAHs and their activity.
We investigated the effect of 8 different PAHs on SMC PLA2 activation and
induction of apoptosis. Our data show that five of the 8 compounds tested cause 3 H-AA
release in a concentration-dependent fashion. The 5 active compounds also induce apoptosis
at a concentration that induce significant 3 H-AA release. In addition, specific PLA2
inhibitors that are selective for Group IV and VI enzymes inhibit 3 H-AA release and
attenuate the apoptotic effect, suggesting that PAHs induce SMC apoptosis by a mechanism
thati nvolves PLA2. Results from cell-free PLA2 activity assays, RT-PCR, and Western
blotting show that SMC express 4 isoforms of PLA2, Group IVa, J3, y, and Group VIJ3 PLA2.
Transfection of SMC with PLA2 isoforms that were the most strongly expressed (Group IV-y
and Group VIJ3) causes a significant increase in 3 H-AA when stimulated with active PAHs as
compared to wild type cells. Our data suggest that both of these enzymes are responsible for
PAR-induced AA release and subsequent apoptosis in SMC with the possibility of Group
IVa and J3 involvement in this effect.
This study demonstrates the involvement of PAHs in EC and for the first time in
SMC. Furthermore, our data suggest that small molecular weight, highly water-soluble
compounds present in Chattanooga creek may be potentially toxic confirming the need for
further studies.
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PART I: Introduction
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BACKGROUND AND SIGNIFICANCE
Polycyclic aromatic hydrocarbons and atherosclerosis

Polycyclic aromatic hydrocarbons (PAHs) are an important class of environmental
xenobiotics that are abundant in the environment and in food. They are formed by
incomplete combustion of organic matter. They also come from automobile exhaust,
tobacco smoke, residential wood, and coal combustion 1•2 . PAHs are highly lipophilic
and, thus readily absorbed from the gastrointestinal tract of mammals. Many studies
indicate that PAHs have toxic, mutagenic and/or carcinogenic consequence3 •4 • There are
more than 100 different PAH compounds that are identified. Sixteen of the common
PAHs typically analyzed have been listed by the Environmental Protection Agency
(EPA) among 129 priority pollutants. Five of those compounds are listed among the 25
hazardous substances that are believed to have the most potential threat to human health
at priority superfund sites5'6 •
PAHs are classified into two groups depending upon their physical and chemical
properties. Low-molecular-weight PAHs, contain three or fewer aromatic rings and high
molecular-weight PAHs, contain more than three aromatic rings3•7•8 • Alkyl and chlorine
substitutions may exist on one or more rings. Those substitutions change the fate and
effect of PAHs often making them more toxic3 '8 • PAHs can also be grouped into
different categories depending on their molecular weight, number of rings present and
water solubility7'8 . Table 1 shows different chemical and physical properties for the
PAHs used in this study7 • PAHs are likely to partition into sediments and soils, with
relatively small concentrations of many PAHs showing up in water due to low solubility.
It has been shown that two-ring compounds are more soluble than heavier three-ring
2

compounds, and thus might be more toxic3 •8 • However, recent studies have shown that
some of the heavier P AHs can exhibit acute water toxicity at levels below solubilities due
to photo-enhanced toxicity in the presence of ultraviolet (UV) or other types of solar
radiation3•7• 8 •
Previous studies of structure-activity relationships of PAHs, have focused mainly
on the genotoxic and tumor-initiating properties of these compounds9• Discrete structural
determinants are required for these effects. It was reported previously that the potent
genetic toxicity of two- to four-ringed PAHs requires a bay- or a bay-like region in the
molecule. Linear PAHs that do not contain these regions are not genotoxic9• The
existence of a discrete structural determinant for activity suggests that these compounds
interact with a protein or proteins in the cell. Whether a ligand binds to a protein can
depend on the size of the ligand. A large molecule may be too bulky to bind the active
site of the protein, whereas a smaller molecule can. Thus, it is likely that both molecular
structure and solubility play important roles in the toxic effects of PAHs7•

10•11

•

PAHs, cigarette smoke and disease

Cigarette smoke (CS) has been implicated as a major risk factor in pulmonary diseases
such as chronic bronchitis, emphysema, carcinogenesis, and atherosclerotic heart
disease12-14• CS contains more than 4,000 constituents including reactive oxygen species,
such as superoxide and hydroxyl radicals3, PAHs, cadmium, carbon monoxide, and
15

nicotine

•

PAHs present in the highest concentrations in CS include methylated

anthracenes (1500 ng/cigarette), substituted and unsubstituted naphthalenes (276
ng/cigarette), acenapthylene (64 ng/cigarette), acenaphthene (46.8 ng./cigarette),
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phenanthrene ( 1 19 ng/cigarette), substituted and unsubstituted fluorenes ( 19 1 ng/
cigarette), fluoranthene (4 1 ng/cigarette), and pyrene (PY; 35.4 ng/cigarette)3• 16 •
The augmentation of atherosclerosis by CS involves endothelial cell (EC) injury
as smokers demonstrate an increase in EC death and loss into the circulation when
compared to non-smokers 1 7 • Several studies have indicated that CS induces EC injury by
apoptosis or programmed cell death 1 8 • Wang and his colleagues showed that CS induced
EC apoptosis, in a dose dependant-manner, that was mediated by transcription factors and
caspase-3 1 8 • Little is known, however, about the specific components of CS responsible
for this effect.
EC injury and phospholipase A2 enzymes

The results of recent epidemiologic studies suggest that EC injury associated with
myocardial infarction may involve the phospholipase A2 (PLA2)/arachidonic acid (AA)
pathway (PLA2/AA) 19 • Consumption of diets high in fish has been shown to reduce by
50% the risk of death due to coronary artery disease in smokers 1 3 . Fish intake protects
against the deleterious effects of smoking due to the presence of ro-3 fatty acids in fish
oils, which act by altering the AA cascade20 • Furthermore, inhibition of AA metabolism
by administration of nonsteroidal antiinflammatory drugs decreases significantly the
incidence of coronary heart disease in smokers2 1 • These results suggest that alterations in
AA metabolism caused by smoking are important in the pathogenesis of smoking
induced atherosclerosis.
We recently demonstrated that PAHs present in CS in high concentration
stimulate PLA2 -mediated release of membrane fatty acids, PLA2 activation and EC
apoptosis, suggesting the involvement of PAHs in the progression of atherosclerosis22 •
4

The family of PLA�s

PLA2 s comprise a broad and diverse family ofenzymes that exhibit different substrate
specificities, cofactor requirements, subcellular localization, and cellular functions23,24.
PLA2 s hydrolyze membrane phospholipids at the sn-2 position, and release many lipid
products that are important either for housekeeping functions such as membrane
remodeling, or for the production ofinflammatory lipid mediators e.g. AA or other fatty
acids25. AA, which is a second messenger, also serves as a substrate for the generation of
eicosanoids25. Eicosanoids are known to be potent inflammatory lipid mediators that are
generated from AA through cyclooxygenase, lipoxygenase, and cytochrome P-450
enzymes23.
Several systems have been used to classify PLA2 s26. In general, mammalian
PLA2 s are classified into three major groups, calcium-dependent secretory (sPLA2),
calcium-dependent cytosolic (cPLA2 ), and calcium- independent cytosolic (iPLA2)23-25.
PLA2 s are also classified according to whether their active site contains a serine or a
histidine residue24. In general, small molecular weight secreted isofonns (Groups I, II,
III, V, IX, and X) have a histidine at the active site; whereas the large molecular weight
intracellular enzymes (Groups IV and VI) have an active site serine. Of the Groups IV
and VI enzymes, several isofonns have been identified23-26. Table 2 summarizes the
general properties of different mammalian PLA2 isofonns23-26.
PLA2 isoforms and apoptosis

Several studies have reported the involvement of groups IVa PLA2 and VIJ3 PLA2 in
apoptotic signal transduction pathways22,24,27-3 1 • Past reports indicate that Group IVa is
involved in tumor necrosis factor-a (TNF-a) -induced apoptosis and that cells from
5

knock-out mice are resistant to the effects of TNF-a.3 1 • However, Fas/Fas L has been
shown to be equally effective in mediating apoptosis in Group IVa. positive and negative
cell lines27 • Upon activation by H2O2 in smooth muscle cell (SMC), IVa. releases AA
that in turn causes phosphorylation of proapoptotic proteins such as; c-Jun and c-fos24 •
Previous studies have also implicated Group VIP in apoptotic cell death caused by
the Fas/Fas-associated death domain (FADD) pathway22•32 . Interaction of Fas with its
ligand activates Group VIP and causes release of fatty acids that induce phosphorylation
of stress-activated protein kinases (SAPK) such as c-jun-N-terminal kinases (JNK.s) and
p38. These kinases cause downstream activation of transcription factors and caspases.
Moreover, there is a positive feedback loop identified, wherein fatty acid-induced caspase
activation causes reciprocal VIP cleavage. The cleaved product exhibits a 2- to 3-fold
increase in PLA2 activity, thus further driving the process of apoptosis 32 • An earlier study
indicates that activation of PLA2 by oxidized LDLs contained within atherosclerotic
plaques results in the release of AA and subsequent activation of SAPK/JNK.s33 • These
enzymes, of which 4 isoforms have been characterized (JNK.-1, JNK.-2 JNK.-3 and p-38),
phosphorylate and activate transcription factors such as c-Jun and transcription factor
activator protein- I (AP-1 ), which play important roles in regulation of cell growth and
apoptosis 16 • The apoptotic pathway regulated by JNKs involves activation of caspases 8
and 9 that subsequently activate caspase-3 1 8 • Apoptotic stimuli generate signals that are
either transmitted across the plasma membrane to intracellular regulatory molecules or
directly target proapoptotic molecules inside the cells. An example of the former
mechanism is the Fas/FasL/FADD pathway. Binding of FasL to Fas recruits the death
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domain protein, FADD, which is required for caspase-8 activation and subsequent
initiation oflethal proteolytic cascades. FADD couples the Fas death receptor to
procaspase-8, and subsequent oligomerization promotes procaspase-8 autoactivation34•35 •
The latter mechanism involves the regulation of mitochondrial function by the Bcl-2
family of proteins. Release ofcytochrome c from the mitochondria is a proapoptotic
signal. Proapoptotic protease activating factor (Apaf-1) is activated upon binding with
cytochrome c after its release from the mitochondria. The antiapoptotic Bcl-2 proteins
downregulate apoptosis by either prevention of cytochrome c release directly, or by
sequestering Apaf-136 . There is also a reciprocal regulation ofBcl-2 by cytochrome c.
Apoptotic signals can block Bcl-2 function, which in turn causes mitochondrial
membrane depolarization and subsequent cytochrome c release, proteolytic activation of
procaspase-9, and subsequent activation of caspase-3 and other lethal proteolytic
cascades36 •
Vascular smooth muscle apoptosis and atherosclerosis

EC are not the only cells that undergo apoptosis during atherosclerosis. There is
compelling evidence that apoptosis of SMC is also important in atherosclerosis 1 6 • SMC
play an important role in the maintenance ofatherosclerotic fibrous plaque strength since
they produce interstitial collagen that provides plaque tensile strength 1 6 • During
atherosclerosis SMC become activated and migrate into the intima to proliferate and
produce extracellular matrix proteins37 • SMC produce collagen that plays an important
role in the maintenance of plaque tensile strength 16 • Recent studies provide convincing
evidence that SMC apoptosis is an important mechanism of SMC loss, reduction of
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plaque tensile strength, and subsequent plaque rupture during atherosclerosis and acute
myocardial infarction38 •

HYPOTHESES AND OBJECTIVES

The central hypothesis ofthis research is that PAHs selectively induce vascular cell (EC
and SMC) injury by a mechanism mediated by PLA2 enzymes.
The first objective of this study was to test the hypothesis that PAHs present in
the environment induce EC injury by a mechanism that involves PLAi-mediated release
ofAA. For this purpose the Chattanooga creek sediments were surveyed for the presence
ofEPA priority PAHs, and the 11 PAHs present in the highest concentrations were
evaluated for their effects on EC PLA2 activation and apoptosis.
PAHs have also been shown by others to activate JNK.s and p-38; however
upstream signal transduction mechanisms have not been determined 1 8 • Since oxidized
LDLs have been shown to be involved in EC apoptosis by a mechanism that involves AA
and JNK., it is possible that PAHs act in a similar fashion 19• For that reason, the second
objective ofthis study was to test the hypothesis that PAHs induce EC apoptosis by a

mechanism that involves PLAi -mediated activation of JNK.s, p-38 and caspases -8, -9,
and -3. For this purpose, the effects of8 PAHs were investigated.
Since SMC loss/injury is known to be important in the process of coronary artery
disease and atherosclerotic disease involving other arteries as we113 7•38 , induction of SMC
apoptosis by cigarette components may represent an important mechanism of smoking
induced augmentation ofcardiovascular diseases. The third objective ofthis study is to
investigate the effects of 9 PAHs on SMC in vitro and tq characterize the roles of
8

different PLA2 isoforms in this effect. In addition, we intend to investigate the effects of
PAHs on FADD expression in order to investigate whether PAHs interact with this
pathway.

9
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Table 1. Chemical and physical properties ofPAHs 1
PAHs

Structure

Molecular weight

Anthracene

CCX)

Water solubility
mg/L

178.24

0.075

192.26

0.039

192.3

0.261

180.25

1.092

180.25

1.092

166.23

1.90

202.26

0.24

178.24

1.65

Anthr1ccnc

1 20-1 2-7

2-Methylanthracene

CCXY�.
2-methylanthr=e

6 1 3- 1 2-7

1-Methylanthracene

OX)

o=o�·
1-m ethylan thraccne

6 1 0-48--0

1-Methylfluorene

1 -m eth y l fl u o re n e

1 7 3 0 -3 7 - 6

2-Methylfluorene

vb-CH,

2-methylfluorene

1 430-97-3

Fluorene

::XO
o£
o9
Fluorene

8 6 -7 3 -7

Fluoranthene

f lu o r 1 n t h c n c
2 0 6 -4 4 -0

Phenantherene

P h c 11 a 11 t b rc11e

S S -0 1 -8
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Table 1 . Continued
Triphenylene

228.3

0.0388

252.32

0.0008

202.26

0. 1 65

228.3

0.00 1 5

2 1 6.29

0.002

Triphcnylcnc

Benzo[k]fluoranthene
Benzo[k)nuoranthenc

Pyrene

Pyrcne

Chrycene
Ch ')'s�nc

2 1 8-0 1 -9

2,3-Benzofluorene
2,3-benzofluormc
92-24-0
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Table 2. Mammalian phospholipase A2 Groups
Size
Substrate
Inhibitor
Ca:2+
(kD) requirements specificity
Apoptosis
profile
Sources
Group
0
a
MM
None
Porcine/human
1
3
1
5
BPB
NIA
IP
MM
BPB
Human/rodents
1 3- 1 7
None
NIA
II
C
0
Human/rat
AA
AACOCF3
,
MAFP
85
<µM
IVa
Human
None
Yes
1 14
<µM
IV P
Human
6
1
None
None
IVy
MM
All
None
BPB
14
V
NIA
Human
None
40
AA
AACOCF3, MAFP,BEL 0
Via
Human
Yes
None
None
85-88
None
None
NIA
BPB
VII Human/mouse/porcine 40-45
None
None
Human
AACOCF3
NIA
26
VIII
MM
14
Human/mouse
BPB
None
X
NIA

vm

It will cleave AA and other fatty acids from the membrane phospholipids.
p-bromophenacyl bromide (non-specific sPLA2 inhibitor).
c Arachidonyl trifluoromethyl ketone (a potent cPLA2 inhibitor).
d Methyl arachidonyl fluorophosphonate (Group IV and VI PLA2 inhibitor).
a

b

PART II: Environmental pollutants activate phospholipase A2 isoforms
and induce apoptosis of human coronary artery endothelial cells
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INTRODUCTION

Several major cities in Tennessee have significant levels ofindustrial pollution, including
Knoxville, Memphis, Nashville, and Chattanooga. South Chattanooga is an old industrial
area where industrial pollutants are found in vapors, aerosols, solutes, particulates, liquids
and sludges. Since 1917, coal carbonization byproducts were discharged into a 2.5 mile
section ofthe Chattanooga creek. A Health Advisory was issued by the Agency for
Toxic Substances and Disease Registry concerning human contact with coal tar deposits
in South Chattanooga in 1993 1 •2 • After U.S. Environmental Protection Agency (EPA)
study in 1994, the creek was placed on the National Priorities List and South Chattanooga
was designated as a Superfund site due to excessive accumulation ofindustrial pollutants
in the air, soil and water. The EPA removed coal-tar deposits and contaminated
sediments from a one-mile section of Chattanooga creek in 1997 and 1998; however, no
remediation has been conducted on the adjacent floodplain2 • Moreover, little information
is available concerning the potential health risks to inhabitants of South Chattanooga.
Exposure to industrial pollutants increases the incidence of several diseases
including cancer, pulmonary and cardiovascular diseases3 • Atherosclerosis and
subsequent heart disease is the leading cause of death in the United States. Recent
epidemiologic studies show a po�itive correlation between levels ofparticulate air
pollution and daily morbidity and mortality due to acute myocardial infarction in major
cities in the United States3 • Another major risk factor for the development of
atherosclerotic vascular disease is cigarette smoking (CS)4. Important toxic constituents
that CS and urban pollution have in common are the polycyclic aromatic hydrocarbons
(PAHs) 3 •4 . Several PAHs have been shown to promote atherosclerosis in animal models;
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however, the exact pathophysiological mechanisms have not been determined 5•6 • It is
likely that endothelial cells (EC) injury plays a role since this is the earliest and most
critical event in the development of atherosclerosis. Indeed, it is well known that the
augmentation of atherosclerosis by CS involves EC injury since smokers demonstrate an
increase in EC death and loss into the circulation when compared to non-smokers 7 •
Numerous studies have demonstrated that cells die in atherosclerotic plaques
through apoptosis8•9 • Apoptosis is characterized by cellular events that include cellular
shrinkage, nuclear condensation, membrane blebbing, and apoptotic body phagocytosis 8 •
Biochemical alterations also occur during apoptosis including alterations in gene
expression and activation of endonucleases that induce DNA fragmentation8 • A role for
the phospholipase A2 (PLA2)/arachidonic acid (AA) pathway in apoptosis is emerging 10t4

PLA2 s comprise a large and diverse family of enzymes that exhibit different
substrate specificities, cofactor requirements, subcellular localizations, and cellular
functions. PLA2s hydrolyze membrane phospholipids at the sn-2 position and release AA
or other fatty acids that are important in the production of over 1 00 biologically active
lipid mediators 1 3 • PLA2 , AA and many of its metabolites induce apoptosis by activating
pathways such as c-Jun-N-terminal kinases (JNK.s) and sphingomyelinases that are
involved in this process 1 3 •
We have demonstrated recently that three PAHs present in high concentration in
CS induce apoptosis of human coronary artery EC (HCAEC) by a mechanism that
involves activation of three different isoforms of PLA2 • 1-methylanthracene, a three-ring
PAH induces apoptosis by activating a Group VI calcium-independent enzyme; whereas
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benzo(a)pyrene exerts this effect by activating a Group IV PLA2 • In contrast,
phenanthrene induces apoptosis by a mechanism that involves two isoforms of PLA2 , a
Group VI enzyme and the lysosomal, acidic, calcium-independent PLA2 (aiPLA2)
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.

The purpose of the present study was to test the hypothesis that P AHs present in
the environment induce EC injury by a mechanism that involves PLArmediated release
ofAA. For this purpose the Chattanooga creek sediments were surveyed for the presence
of1 6 EPA ·priority PAHs and the PAHs present in the highest concentrations were
evaluated for their effects on EC PLA2 activation and apoptosis.

MATERIALS AND METHODS
Materials

All PAHs were obtained from Aldrich (Milwaukee, WI). [5,6,8,9,1 1 ,1 2,1 4,1 5-3H]
arachidonic acid (3H-AA; 200-240 Ci/mmol) was purchased from American
Radiolabeled Chemicals (St. Louis, MO). Bromoenol lactone (BEL) and
methylarachidonoyl fluorophosphonate (MAFP) were obtained from Biomol (Plymouth
Meeting, PA). Anti-PARP antibody was obtained from Pharmingen (San Jose, CA).
Cell death elisa plus apoptosis kit was obtained from Roche (Indianapolis, IN). The
antibody to Group VI iPLA2 was obtained from Upstate Biotechnology (Lake Placid,
NY) and the antibody to Group IVy was produced as described previously 1 5 •
Methods

Creek sediment sample extractions for PAH.
All creek bottom sediment samples were collected along Chattanooga creek and stored
immediately under dry ice. These samples were transferred to a -80 °C freezer in the
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laboratory until hot solvent extractions were performed. Soil extraction for PAHs was
performed using a commercially available Accelerated Solvent Extractor (ASE 300,
Dionex Corp., Sunnyvale, CA). The extraction protocols and quality control procedures
followed were according to EPA SW-846 Method 3545A (pressurized fluid extraction)
and Method 8270D (semivolatile organic compounds by GC/MS). A 10 g (wet weight)
of sediment sample was thoroughly mixed with 10 g of Hydromatrix (inert diatomaceous
earth, Varian Inc.,Palo Alto, CA). Each sample was extracted at 100 °C with methylene
chloride and acetone (1:1, v/v) at a pressure of 1500 psi for a total time of 20 min. A
surrogate spike mixture was added to each sample before the extraction procedure to
measure extraction efficiency. Method blanks and laboratory controls were carried out
using the same extraction protocol but with uncontaminated background soil collected
from Ooltewah, TN {Tupelo series soil). All sample extracts were concentrated to a final
volume of 2 ml (in an amber vial) and stored at -20 ° C pending further analyses.
Sample extracts were analyzed using a Hewlett Packard gas chromatograph (GC, Model
6890) equipped with Mass Selective Detector (MSD, Model 5973) and a HP auto
sampler. Helium was used as the carrier gas, and a constant flow rate (0.6 mVmin) was
maintained by electronic pressure control. A DB-5MS column (30 m x 0.25 mm i.d.,
J&W Scientific, Folsom, CA) was used for separating PAH compounds in the GC
according to EPA Method 8270D. An internal standard mixture was added into each GC
sample before the analysis. The concentration of each of the 16 EPA priority PAH
compounds in the sediment samples were quantified based on analysis of a PAH standard
mixture containing the 16 PAH compounds. The concentration of each of the 16 PAH
compounds was calculated using the following equation:
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A

A

cone. = std.cone. x � x _L
A1s Axs
where std. cone. is the concentration of the PAH compound in the standard mixture, A1ss
is the area of the internal standard peak present in the PAH standard, A 1s is the area of the
samples internal standard peak, Ax is the area of the PAH compound peak within the
sample analysis, Axs is the area of the compound peak in the PAH standard mixture, and
cone. is the concentration of the PAH compound in the sample.
Cell culture
HCAEC were obtained from Clonetics (San Diego, CA) and were maintained in
microvascular EC growth media (Clonetics, San Diego, CA) containing 5% fetal bovine
serum. The cells were maintained at 37 °C in an atmosphere of 5% CO2/95% 02 •
PLA2 activity/AA release
HCAEC were seeded into 6-well plates (1 05 cells/well) in growth medium. At 75 %
confluence, cells were prelabeled for 24 hrs with 0.25 µCi/ml of 3 H-arachidonic acid {3 H
AA). The cells at 80-90% confluency were washed twice with Hanks' balanced salt
solution (HBSS) and equilibrated for 45 min in HBSS + 0. 1 % bovine serum albumin
(BSA). BSA was used to inhibit reacylation and metabolism of released 3H-AA thus the
data reflect cumulative release of 3H-AA. Radiolabeled cells were exposed to various
concentrations of PAHs present in the highest concentrations in the contaminated section
of the Chattanooga creek. These included 1 -methylanthracene ( 1 -MA), 2methylanthracene (2-MA), anthracene (AN), fluorene (FL), 1 -methylfluorene (1-MF), 2methylfluorene (2-MF), phenanthrene (PA), fluoranthene (FA), chrysene (CH),
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benzo[k]fluoranthene (B[k]F), and pyrene, (PY) (Figure 1 1 ). Cells were exposed to
P AHs or vehicle for 60 min and cumulative release of3H-AA into the medium was
measured by scintillation counting and expressed as percent of total cellular radioactivity.
To determine the PLA2 isoforms activated by various P AHs, 3H-AA release was
measured in stimulated HCAEC in the presence and absence of bromoenol lactone [BEL;
inhibitor ofGroup VI iPLA2] 1 4 , and methylarachidonoyl fluorophosphonate [MAFP;
inhibitor Groups IV and VI PLA2 s] 14 •
Apoptosis
Two methods were used to measure apoptosis caused by PAHs: Western analysis for the
cleavage product ofpoly-ADP-ribose polymerase (PARP) and ELISA for detection of
histone fragmentation.
PARP cleavage was determined after treatment with PAHs or vehicle (DMSO)
for 6 hrs. Crude extracts of protein were prepared by suspending in ice-cold sample
buffer (62.5% Tris-HCL, pH 6.8, 6 M urea, 1 0% glycerol, 2% SDS, 0.003%
bromophenol blue, 5% �-mercaptoethanol) containing protease inhibitors. Cells were
lysed by sonication on ice for 2 X l O s, 40% duty and lysates (40 µg ofprotein) subjected
to 8 % SDS-polyacrylamide gel electrophoresis. The proteins in the gel were transferred
to nitrocellulose membranes via a semi-dry blotting apparatus, the membrane blocked in
5% nonfat dry milk in phosphate buffer saline (PBS)/0.1% Tween 20, and incubated
overnight at 4 °C with an anti-PARP antibody. Visualization was enhanced by
chemiluminescence (ECL) (Amersham Pharmacia Biotech).

1

See all figures and tables in appendix
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Apoptosis was also evaluated fluorimetrically utilizing the Cell death elisa plus kit
for detecting histone fragmentation. Cells seeded into 6-well plates were treated at 8090% confluency with 30 µM P AHs or vehicle for 3 hrs. Histone fragmentation was
evaluated in cells treated with all eight PAHs in the presence and absence ofthe PLA2
inhibitor MAFP.. Cells were then washed with warm PBS, lysed and incubated with
antihistone-biotin and anti-DNA-POD at room temperature for 2 hrs. After washing with
incubation buffer, 1 00 µ1 of substrate solution was added to develop the color and
measurements made at 405 nm using a plate reader. Additional preliminary experiments
were performed to ensure that neither the PAHs nor the inhibitors interfered with this
fluorescent assay.
Cell-free PLA2 activity
To verify results obtained with intact cells, cell free PLA2 activity was measured in whole
cell sonicates as described previously 16 • Cells were washed in Ca2+-free PBS containing
5 mM EDTA and 1 mM PMSF, resuspended in cold homogenizing buffer, placed on ice,
and sonicated. Light microscopy was used to verify that the cells were broken. Based on
previous inhibitor studies, experiments were designed to assay for Groups IVa, p, y and
VIJ3 enzymes. Since Groups IVa and IVy prefer AA over linoleic acid at the sn-2

position, the substrate l -palmitoyl-2- [arachidonoyl-1 - 14C] phosphatidylcholine ( 14C-AA
PC) was used to assay for their activities. Since Groups IV P and VIP are arachidonoyl
nonselective, the substrate 1 -palmitoyl-2-linoleoyl [linoleoyl-1 - 1 4C] phosphatidylcholine
(

C-LA-PC) was used to assay for their activities. Substrates were dried under nitrogen

14
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and resuspended by sonication in assay buffer to a final optimum concentration as
determined in preliminary experiments.
To determine the role of calcium in activation of PLA2, assays were performed in
the presence of either 5 mM CaCh or 5 mM EGT A. To determine if PAHs activate PLA2
enzymes by interacting directly with the proteins, cell lysates were incubated with 1 4C
AA-PC or 14 C-LA-PC for 30 minutes in the presence and absence of PAHs. Experiments
were also performed in the presence and absence of inhibitors (MAFP and BEL) to
validate the selectivity of inhibitors for specific isoforms. Cell-free PLA2 assays are
designed to target selected isoforms and therefore, are an effective means to validate the
specificity of inhibitors for select PLA2 isoforms. Reactions were terminated by addition
of chloroform-methanol, 2: 1 (v/v); the chloroform layer extracted and spotted on silica
gel thin layer chromatography plates. The plates were chromatographed in a neutral lipid
solvent and the lipids visualized with Ii vapor. The zones corresponding to fatty acid and
phospholipid were cut out and radioactivity determined by scintillation counting.
Western analysis of PLA2 isoforms
To determine if PAHs upregulate PLA2 isoforms, cells were treated with four active
compounds (1-MA, PA, FA, 1-MF), 1 inactive compound (AN) or vehicle for 4 hours
and Western blotting performed with cell lysates. After treatment the cells were washed
with PBS and then lysed in RIP A buffer (50mM Tris, 1 50 mM NaCl, 1 % SDS, 0.5%
sodium deoxycholate, 1 mM DTI, 1 00 µM p-4-(2-aminoethyl)-benzenesulfonyl fluoride,
1 µM pepstatin, and 1 00 µM leupeptin). The lysate was centrifuged at 1 0,000 g for 20
min and the supernatant subjected to 1 0% SDS-polyacrylamide gel electrophoresis and
28

transferred onto nitrocellulose membranes. The membranes were probed with antibodies
against Group VIJ3 PLA2 and. Group IVy PLA2 • Bands were visualized by enhanced
ECL.
Statistical analysis
Data are expressed as mean ± SEM. Data were analyzed by analysis of variance, and
group means were compared using Student-Newman-Keuls'. Appropriate
transformations were performed on all data that did not follow a normal distribution (e.g.
percent data). In addition, when variances are not equal or if transformation failed to
normalize the data, nonparametric statistics (Mann-Whitney rank sum test) were used.
For all studies, the criterion for statistical significance was p<0.05.

RESULTS
PAH levels found in contaminated and uncontaminated sediment from Chattanooga
creek

The PAH levels measured in the Chattanooga creek bed are shown in Table 1. Very low
or non-detectable levels ofPAHs were found in the uncontaminated reference area;
however, extremely high levels were observed in the portion ofthe creek considered to
be contaminated. These levels ranged from 10,625 mg/kg soil (phenanthrene) to 97
mg/kg soil for fluorene compounds (Table 1). These compounds were used to evaluate
potential toxicity ofPAHs found in the Chattanooga creek. Eleven PAHs found in the
highest concentrations in the creek were evaluated for their ability to activate PLA2s and
induce apoptosis.
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PAH-induced PLA� activation and 3H-AA release

Little 3 H-AA release was observed from unstimulated HCAEC or from cells exposed to
AN and 2-MA; however, 1-MA, caused significant, concentration-dependent release of
3

H-AA (Figure 2A). FA and PA induced significant 3H-AA release; however, the

responses to CH, PY, and B[k]F were not different from vehicle-treated control (Figure
2B). However, FL and its methylated derivatives all caused concentration-dependent 3 H
AA release (Figure 2C). Pretreatment with MAFP, an inhibitor of Group IV and VI
PLA2 isoforms, attenuated significantly the release of 3H-AA from cells treated with 1MA, 1-MF, 2-MF, FL, FA, and PA (Figure 3). However, BEL, the inhibitor of Group VI
enzymes, attenuated only the response to 1-MA, FA, and PA (Figure 4).
PAR-induced apoptosis

All six compounds that caused 3 H-AA release also induced apoptosis as determined by
histone fragmentation ( 1-MA, 1-MF, FL, 2-MF, FA, and PA); however, the compounds
that failed to induce 3H-AA release also failed to induce apoptosis (AN, 2-MA, CH,
B[k]F, and PY (Figure SA). To verify the results with histone fragmentation, Western
analysis for the cleavage product of PARP was evaluated for active, and 2 inactive
compounds (Figure SB). 1-MA, 1 -MF, 2-MF, FL, FA, and PA, compounds that activated
PLA2 , also induced apoptosis. The two compounds, AN and 1-MA, that did not cause
3

H-AA release, also did not induce apoptosis.

Inhibition of apoptosis by MAFP

To investigate whether PLA2 activation is required for PAH-induced apoptosis, histone
fragmentation was determined in the presence and absence of the PLA2 inhibitor, MAFP.
Apoptosis induced by all six compounds was significantly inhibited by MAFP (Figure 6).
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Histone fragmentation experiments were not performed with BEL because it also
functions as a protease inhibitor and as a consequence would inhibit caspases and
apoptosis due to effects unrelated to PLA2 inhibition.
Cell-free PLA7 assays

To characterize further the PLA2 isoforms functioning in HCAEC, cell-free assays were
performed. As can be seen in Figure 7A, when 14C-AA-PC was used as a substrate to
assay for Group IV enzymes, PLA2 activity was significantly greater than blank (DMSO,
no protein) and MAFP, but not BEL, attenuated that response. Activity was also not
significantly different in the presence and absence of calcium. Furthermore, treatment of
lysates with active PAHs did not enhance PLA2 activity (Figure 7B). When 14C-LA-PC
was used as a substrate, there was significant PLA2 activity under calcium-free conditions
and this activity was inhibited significantly by both MAPP and BEL (Figure 8A).
Treatment oflysates with active PAHs failed to cause a change in activity (Figure 8B).
PAH-induced expression of PLA� isoforms

The results ofthe cell-free assays suggested that the predominant activity in HCAEC was
due to the Group VIJ3 (this enzyme prefers linoleic acid at the sn-2 position, is calcium
independent and inhibited by BEL and MAPP) and the Group IVy (this enzyme prefers
AA, is calcium-independent and inhibited only by MAPP). Therefore, experiments were
performed to evaluate whether incubation with PAHs would result in upregulation of
these two isoforms. Treatment for 4 hours with 1-MA, PA, and FA, but not vehicle, I 
MF, or AN caused a significant increase in expression ofthe Group VIJ3 enzyme;

31

whereas the Group IVy enzyme was significantly upregulated by all active compounds
(PA, FA, 1 -MF, and 1 -MA) but not an inactive compound (AN) or vehicle (Figure 9).
DISCUSSION

This study confirms that significant levels of PAHs are present in the Chattanooga creek
as a result of industrial contamination. Moreover, 6 of the 1 1 compounds were toxic to
EC at low micromolar concentrations. They induced 3 H-AA release in a concentration
dependent manner, and this event preceded the onset of apoptosis. Inhibition of fatty acid
release with selective PLA2 inhibitors significantly attenuated PAH-induced apoptosis.
These data confirm previous studies and provide compelling evidence that PAHs cause
EC death by a mechanism that involves PLAi-induced release of fatty acids from the sn-2
position of membrane phospholipids.
Of the three anthracene compounds, only 1 -MA caused release of 3 H-AA and
apoptosis. 2-MA and AN caused neither effect. Since there are no major differences in
water solubility between these compounds, the data are suggestive of a discrete structural
determinant necessary for activation of PLA2 and subsequent apoptosis. The major
differences between 1 -MA, 2-MA, and AN are that 1 -MA is a compound that contains a
bay-like region on the molecule, whereas 2-MA and AN are linear compounds (Figure 1 ).
These results are consistent with previous studies by others that have demonstrated that
bay- and bay-like regions are required for PAH-induced activation of c-jun-N-terminal
kinase 1 7 • The results with CH and B[k]F; however, inconsistent with this hypothesis
since these compounds have bay regions but were inactive. One possibility for this is that
these compounds are significantly bulkier than the other active compounds with bay or
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bay-like regions. The existence ofa discrete structural determinant for activity suggests
that these compounds interact with a protein or proteins in the cell. Whether a ligand
binds to a protein can depend on the size of the ligand. A large molecule may be too
bulky to bind the active site of the protein, whereas a smaller molecule can. Another
possible explanation for these results is that CH and B[k]F are significantly less water
soluble (0.002 mg/L and 0.0008 mg/L, respectively) than the active compounds FA (0.26
mg/L) and PA (1.6 mg/L). However, solubility cannot explain all the results. If so, it
would be expected that a direct relationship would exist between water solubility and
PLA2 activation and this was not the case. For example, FA was significantly more
active than PA in activating PLA2 and inducing apoptosis, but it was an order of
magnitude less soluble than PA. Thus, it is likely that both molecular structure and
solubility play important roles in the effects ofPAHs on EC PLA2 activation and
apoptosis 1 8-20 •
The results of this study suggest that the three active compounds with bay- or bay
like regions (PA, 1 -MA, and FA) activated two isoforms ofPLA2 • MAFP is an inhibitor
of Group IV enzymes, IVa, � and y. PLA2 IVa is an 85 kD enzyme that is arachidonoyl
selective and dependent on calcium for phosphorylation and activation. Group IV� is an
1 1 4 kD arachidonoyl-nonselective enzyme that is also calcium-dependent u ·2 1 • In
contrast, Group IVy is a 61 kD protein that lacks the calcium-binding domains of the
other two isoforms 12•22•23 • Results from cell-free PLA2 assays provide strong evidence
that the Group IV isoform targeted by PA, 1 -MA, and FA is IVy. Evidence for this
conclusion is provided by the fact that addition of calcium to the assay buffer did not
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cause an increase in PLA2 activity. Moreover, only MAFP inhibited this effect. The lack
of inhibition by BEL rules out the possibility that this assay was measuring Group VI
enzymes. In addition, Westem blotting after longterm exposure to PA, 1-MA, or FA
caused significant induction of Group IVy expression.
The data suggest that these three PAHs also activate Group VIP PLA2 and this
effect is also responsible for apoptosis of EC. The group VI inhibitor, BEL, also caused
inhibition of 3 H-AA release and apoptosis of EC after treatment with PA, 1-MA or FA.
In addition, long-term exposure to the three PAHs caused a significant increase in
expression of the Group VIP enzyme. However, BEL was significantly less efficacious
than MAFP in inhibiting PLA2 activity and apoptosis, suggesting a lesser role for the
Group VI enzyme in the effects of these PAHs.
All three fluorene compounds activated PLA2 and induced apoptosis. PLA2
activation, AA release and apoptosis were inhibited significantly by MAFP, but not BEL.
Also, a representative compound, 1-MF, increased expression of the Group IVy enzyme,
but not the Group VIP enzyme. These data suggest that fluorene compounds induce
apoptosis by activating Group IVy.
When cell lysates were exposed to active PAHs and cell free PLA2 activity
measured, no differences were seen in Group IVy or VIP activity when compared to
vehicle control. These data provide strong evidence that PAHs do not act by directly
interacting with PLA2 enzymes and provide support for the activation of upstream
signaling proteins. Many of the compounds studied bind the aryl hydrocarbon receptor,
albeit with low affinity24 and activation of this receptor has been shown to induce
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apoptosis25. The possibility that these compounds bind other, as yet, unidentified
-receptors that are involved in activation ofPLA2 also cannot be excluded. Indeed, a 4 s
PAH-binding protein has been identified and is now known to be glycine N-methyl
transferase26, thus indicating the potential for these compounds to bind and alter the
activity ofmore than one protein in the cell. Fas/Fas Ligand-induced apoptosis involves
the activation ofGroup VIP 10 ; therefore, it is possible that the three PAHs that caused
apoptosis by a mechanism that involved that enzyme activated the Fas pathway.
PLA2 activation by PAHs may also be related to the ability of these compounds to
induce oxidative stress. It is well known that oxygen radicals are produced during the
cellular metabolism ofPAHs27. Moreover, both the Group VI and the Group IVP
enzymes are activated by oxidative stress, and oxygen radicals like hydrogen peroxide
can induce apoptosis ofEC22.
Another plausible mechanism for the effects ofPAHs on PLA2 activity is,
because oftheir lipophilicity, they may be able to enhance the interaction ofthe PLA2
enzymes with their substrates. For example, the Group VI enzyme is ~80 kD in size, but
the target size of the catalytically active enzyme is 337 +/- 25 kD, indicating that it exists
as a large oligomeric coinplex28. PAHs may facilitate the assembly of this complex thus
causing an increase in the activity of the enzyme. Indeed, other lipophilic compounds
have been shown to facilitate assembly ofprotein complexes. One example of this is the
NADPH oxidase enzyme that is responsible for the production of superoxide anion2 1 ·22.
This enzyme exists in its active form as a complex of several proteins and cofactors. AA,
because ofits_ lipophilicity, induces a conformation that is required to achieve proper
assembly of the protein complex22. The question of whether PAHs activate PLA2
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isofonns by inducing oxidative stress, enhancing phospholipid/enzyme interactions or by
interacting with signaling proteins is the subject of future investigations.
Less information is available about the means by which exposure to particulate air
pollution causes heart disease; however, the mechanism by which CS induces heart
disease is better understood. Since CS contains many of the toxicants present in urban
pollution, studies examining the pathophysiology of smoking-induced heart disease can
be extrapolated to the effects of urban pollution. A 20 year prospective study provided
compelling evidence for a link between activation of the PLA2/AA cascade and heart
disease in smokers. The Honolulu Heart Project initiated in 1 968 followed a cohort of
8006 Japanese-American men aged 45 to 65 years of age. The results of this study
demonstrated clearly that mortality and morbidity due to coronary heart disease was
significantly less (50%) in heavy smokers who consumed diets high in ro-3 fatty acids4,
compounds known to inhibit the AA pathway at several different levels29 . The same
protection was not observed in non-smokers4 • This study, in addition to others5,30,
suggests that components of CS activate this cascade. Since EC loss/injury is known to
be important in the process of coronary artery disease and atherosclerotic disease
involving other arteries as well, induction of endothelial cell apoptosis by cigarette
components may represent an important mechanism of smoking-induced augmentation of
cardiovascular diseases. Identification of specific structural requirements for PLA2
activation and subsequent EC apoptosis may provide information about the potential
toxicities of PAH compounds found in CS as well as in the environment. This
information may prove to be useful in risk assessment and in discovery of effective
preventative and therapeutic strategies in patients at risk for heart disease.
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SUMMARY

Our results show that Chattanooga creek contains extremely high levels of 11 out of 16 EPA
priority PAHs. The levels ranged from 10,625 mg/kg soil (phenanthrene) to 97 mg/kg soil
for fluorene compounds. Six out of the 11 compounds studied, found in the creek or in CS,
activate the AA cascade and induce apoptosis of EC. Three of the 11 PAHs cause these
effects by activating and increasing the expression of two different isoforms of PLA2 ; the
Group VIP and the Group IVy enzymes. Furthermore, three out of 11 activated and increase
expression of only the Group IVy PLA2 • PLA2 activation and release of AA was associated
with an increase in apoptosis as measured by histone fragmentation and cleavage of P ARP.
From these results, we hypothesize that the water solubility as well as the molecular
structures of the compounds play important roles in the effects of PAHs on EC PLA2
activation and apoptosis. These data suggest that small molecular weight; highly water
soluble compounds present in high concentrations in the Chattanooga creek and CS may be
potentially toxic confirming the need for further studies.
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1 -m ethylanthracene
6 1 0-4 8-0

2-methylanthracene

Anthracene
1 20-1 2-7

61 3-12-7

Fluorene

1 -m ethylflu o rene

2-methylfluorene

86-7 3 -7

1 73 0-3 7 -6

1430-97-3

Phenanthrene
85-0 1 -8

C hrys e n e
2 1 8-0 1 -9

F l u o ra n th e n e
2 0 6 -4 4 -0

Pyrene
2
1 9-00-0

B e n z o [k] fl u o r a n thcm e
2 0 7 -0 8 -9

Figure 1. Structures of polycyclic aromatic hydrocarbons. Antrhracene (AN), 2methylanthracene (2-MA), and pyrene (PY) are linear structures. 1 -metheylanthracene
(1 -MA), and 1 -methylfluorene (1 -MF) have bay-like region formed by methyl group.
Fluorene (FL), 2-methylfluorene (2-MF), fluoranthene (FA), chrysene (CH),
benzo[k]fluoranthene (B [k]F), and phenantherene (PA) have bay-region.
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Table 1 . Polycyclic Aromatic Hydrocarbons Detected in Sediment From Chattanooga
Creek
Polycyclic Aromatic
Hydrocarbons
Anthracenes
Pyrene
Benzo[k]fluoranthene
Chrysene
Fluoranthene
Fluorenes
Phenanthrene
ND=not detected

Background (mg/kg soil)

ND
8
ND
1
8
ND
ND
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Contaminated (mg/kg
soil)
2622
67 1 1
1 023
2088
8563
97
1 0625
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Figure 2. 3 H-arachidonic acid (3 H-AA) release from human coronary artery endothelial
cells. Figure 2 A shows 3H-AA release induced by 1 -methylanthracene (1 -MA), but not
by anthracene (AN) or 2-methylanthracene (2-MA). Cells were prelabeled with 3H-AA
and stimulated for 1 hour with vehicle or various concentrations of 1 -MA, AN, or 2-MA
as described in Materials and Methods. Cumulative release of 3H-AA into the medium
was measured by scintillation counting. *Significantly different from vehicle-treated
control; n=6.
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Figure 2. Continued. Figure 2 B shows 3 H-arachidonic acid (3H-AA) release from human
coronary artery endothelial cells induced by fluoranthene (FA) and phenanthrene (PA),
but not chrysene (CH), pyrene (PY), or benzo[k]fluoranthene (B[k]F). Cells were
prelabeled with 3H-AA and stimulated for 1 hour with various concentrations ofFA, PA,
CS, PY, B[k]F, or vehicle as described in Materials and Methods. Cumulative release of
3 H..;AA into the medium was measured by scintillation counting. * Significantly different
from vehicle-treated control; n=6.
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Figure 2. Continued. Figure 2 C shows 3H-arachidonic acid {3H-AA) release from human
coronary artery endothelial cells induced by fluorene fL), 1 -methylfluorene (1 -MF), and
2-methylfluorene (2-MF). Cells were prelabeled with H-AA and stimulated for 1 hour
with various concentrations of FL, 1 -MF, 2-MF, or vehicle as described in Materials and
Methods. Cumulative release of 3H-AA into the medium was measured by scintillation
counting. *Significantly different from vehicle-treated control; n=6.

48

5 -,-----r----,-----r----r-----r---.-------......
- PAH
WIWJ PAH+MAFP

o --
DMSO

1-MA

1-MF

2-MF

FL

FA

PA

Figure 3. Inhibition of PAR-induced 3H-AA release from human coronary artery
endothelial cells by methylarachidonoyl fluorophosphonate (MAFP). Cells prelabeled
with 3 H-AA were pretreated with 1 0 µM MAFP or vehicle for 30 min and stimulated
with 30 µM 1 -MA, FL, 1 -MN, 2-MN, FA, PA, or vehicle for 1 hr. Release of 3H-AA into
the medium was measured as described in Materials and Methods. * Significantly
different from response obtained in the absence of inhibitor; n=6.
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Figure 4. Inhibition of PAR-induced 3 H-AA release from human coronary artery
endothelial cells by bromoenol lactone (BEL). Cells prelabeled with 3 H-AA were
pretreated with 7.5 µM BEL or vehicle for 30 min and stimulated with 30 µM 1 -MA, FL,
1-MN, 2-MN, FA, PA, or vehicle for 1 hr. Release of 3 H-AA into the medium was
measured as described in Materials and Methods. *Significantly different from response
obtained in the absence of inhibitor; n=6.
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Figure 5. Apoptosis of human coronary artery endothelial cells induced by PAHs. Figure
5 A shows histone fragmentation for cells treated with 30 µM 1-MA, AN, 2-MA, FL, I 
MF, 2-MF, FA, PA, CH, B[k]F, PY, or vehicle for 2 hr and apoptosis determined by
detection of histone fragmentation as described in Materials and Methods. *Significantly
different from vehicle-treated control; n=9.
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85 kD
Figure 5. continued. Figure 5 B shows apoptosis ofhuman coronary artery endothelial
cells induced by different PAHs. Cells were exposed to PAHs for 6 hrs and apoptosis
was determined by detection ofPARP cleavage product (inactive form, ,..., 85 kD) as
described in Materials and Methods. PARP cleavage caused by PAHs, 1 -MA, FL, 1 -MF,
2-MF, FA, and PA but not with 2-MA, AN, or vehicle. n=3.
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Figure 6. Inhibition of PAH-induced apoptosis of human coronary artery endothelial cells
by the Group VI and IV PLA2 inhibitor, MAFP. Cells were pretreated for 30 minutes
with 10 µM MAFP or vehicle and exposed to 30 µM 1-MA, FL, 1-MF, 2-MF, FA, PA, or
vehicle for 2 hr and apoptosis determined by detection of histone fragmentation as
described in Materials and Methods. * Significantly different from vehicle-treated control;
n=9.
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Figure 7. PLA2 activity in HCAEC. Figure 7 A shows human coronary artery endothelial
cells exhibit significant Group IVy activity. Assay conditions were optimized for
characterization of Group IV enzymes and release of 1 4C-labeled arachidonic acid
measured in the presence and absence of calcium, BEL or MAFP as described in
Materials and Methods. PLA2 activity from EC lysate displayed significant activity that
was not different in the presence and absence of calcium. MAFP, but not BEL, inhibited
significantly cell-free PLA2 activity; n=9. *Significantly different from results obtained
in the absence of protein (blank). #Significantly different from results obtained in the
absence of inhibitor, p<0.05; n=9.
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Figure 7. Continued. PLA2 activity in HCAEC. Figure 7 B shows treatment with PAHs
does not enhance cell-free Group IVy activity. Cell lysates were treated with 1-MA, 1MF, PA, FA, or vehicle and cell-free PLA2 activity ev-aluated as described in the legend
to Figure 6A. PLA2 activity was not significantly different in the presence and absence of
PAHs. * Significantly different from response obtained in the absence of protein, p<0.05;
n=9
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Figure 8. PLA2 activity in HCAEC. Figure 8 A shows human coronary artery endothelial
cells exhibit significant Group VIP PLA2 activity. Assay conditions were optimized for
characterization of Group Vlf3 PLA2 and release of 1 4C-linoleic acid measured as
described in Materials and Methods. Endothelial cells displayed significant Group Vlf3
PLA2 activity. Both MAFP and BEL inhibited significantly cell-free PLA2 activity.
* Significantly different from results obtained in the absence of protein (blank).
#Significantly different from results obtained in the absence of inhibitor, p<0.05; n=9.
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Figure 8. Continued. PLA2 activity in HCAEC. Figure 8 B shows treatment with PAHs
does not enhance cell-free Group VIP activity. Cell lysates were treated with 1-MA, 1MF, PA, FA, or vehicle and cell-free PLA2 activity evaluated as described in the legend
to Figure 7A. PLA2 activity was not significantly different in the presence and absence of
PAHs. * Significantly different from response obtained in the absence of protein, p<0.05;
n=9.
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Figure 9. Effect of PAHs on expression of Group IVy and VI(3 PLA2 isoforms. PAH
induced expression of PLA2 enzymes was determined by Westem blotting with
antibodies specific for VIp and IVy PLA2 enzymes after treatment for 4 hrs with vehicle
or active PAHs ( I -MA, FL, I -MF, FA, PA). I-MA, FA, and PA induced expression of
both Group VI(3 and IVy enzymes; however, I -MF increased expression of only Group
IVy, n=3.
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· PART III: Polycyclic Aromatic Hydrocarbons Induce Apoptosis of
Human Coronary Endothelial Cells: Evidence for the Involvement of
Stress-Activated Protein Kinases, Caspases, and Phospholipases
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INTRODUCTION

Cigarette smoking (CS) is the number one cause of preventable, premature death in the
United States today. It is a major risk factor for atherosclerosis and related
cardiovascular diseases 1 • At present, approximately four million people worldwide die
each year from tobacco-related cardiovascular diseases2 • However, the exact
pathophysiological mechanisms of smoking-induced heart disease have, not been fully
established3 •
Recent epidemiologic studies show a positive correlation between exposure to
particulate air pollution or CS, and morbidity and mortality due to acute myocardial
infarction2 • CS was associated with a 50% increase in the progression of atherosclerosis
and passive smoking was associated with a 25% increase4 . Several clinical studies
provide compelling evidence that the phospholipase A2 (PLA 2)/arachidonic acid (AA)
cascade plays an important role in the pathogenesis of smoking-induced cardiovascular
diseases5• 8 • In a 20 year retrospective study, smokers who ate a diet high in fish were
significantly protected from morbidity and mortality due to acute myocardial infarction3 •
This protection was not seen in non-smokers. Moreover, several studies demonstrated
that non-steroidal anti-inflammatory drugs protect significantly against the deleterious
effects of smoking9 . Both of these interactions act by inhibiting the PLA2/AA cascade,
suggesting that this pathway is important in the mechanism by which smoking causes
heart disease.
Polycyclic aromatic hydrocarbons (PAHs) are an important class of
environmental xenobiotics that are present in high concentrations in environmental
pollution and in the tar fraction of CS7 • Several studies using animal models have
60

demonstrated that PAHs present in high concentrations in CS and in environmental
pollution promote atherosclerosis 1 •

4

•

Recent studies in our laboratory suggest that the

mechanism of this effect may be at least, in part, due to PLA 2/AA-mediated endothelial
cells (EC) apoptosis.
Injury to EC is an early and critical event in the development of atherosclerosis
and smoking is known to augment EC injury. Smokers demonstrate a significant increase
in EC death and loss into the circulation when compared to non-smokers5 • This injury to
EC likely involves apoptosis or programmed cell death, since several studies indicate that
apoptosis of EC is a key event during atherosclerosis5•

8

•

EC apoptosis is induced by

several proatherosclerotic factors, thus suggesting the importance of EC apoptosis in
atherogenesis. These factors include oxidized LDLs 1 , angiotensin 119 , and high glucose
concentrations 1 0 •
We found that PAHs may also promote atherosclerosis by inducing EC
apoptosis 1 1 • We demonstrated that 1-methylanthracene, benzo(a)pyrene, and
phenanthrene caused EC apoptosis by a mechanism that involved the PLA2/AA pathway.
The three PAHs caused concentration and time-dependent release of 3 H-arachidonic acid
(3 H-AA) from human coronary artery EC (HCAEC) and subsequent EC apoptosis. These
effects were inhibited by 3 different PLA2 inhibitors, suggesting the involvement of 3
different PLA2 isoforms in AA release and EC apoptosis 1 1 • Significant release of AA
was seen within 10 minutes after exposure of EC to PAHs, however apoptosis was not
seen until 2 hrs after treatment. Since apoptosis involves alteration in gene transcription,
this delay in effect was likely due to an effect of the PLA2/AA pathway on gene
expression.
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The PLA2/AA cascade is complex with more than 100 biologically active
mediators. Recent studies provide compelling evidence for a role of this cascade in
apoptosis 1 2• 1 3 • One mechanism by which AA induces apoptosis is by activation of stress
activated protein kinases (SAPKs)/c-Jun-N-terminal kinases (JNKs) 1 4• 1 5 • Previous
studies indicate that activation ofPLA2 by oxidized LDLs contained within
atherosclerotic plaques results in the release ofAA and subsequent activation of
SAPKIJNKs 1 6 • These enzymes, of which 4 isoforms have been characterized (JNK-1,
JNK-2, JNK-3, and p-38), phosphorylate and activate transcription factors such as c-jun
and transcription factor activator protein-1 (AP-1), which play important roles in
regulation ofcell growth and apoptosis 1 7 • The apoptotic pathway regulated by JNKs
involves activation ofcaspases -8 and -9 that subsequently activate caspase-3 1 8 .
Caspases are a family of cysteine-dependent, aspartate-specific proteases that
work together in a cascade triggered by apoptosis signaling. Caspases are considered to
be the major executioners in the apoptotic pathway. Caspase-3 cleaves the cytoskeletal
and nuclear matrix proteins and causes intemucleosomal cleavage ofDNA. One such
protein is poly(ADP)ribose polymerase (PARP), a nucleosomal protein that can be used
as a marker of apoptosis when this enzyme is cleaved by caspase-3 fragments of 85 and
31 kD 1 9 • Previous studies have shown that CS induces EC apoptosis through caspase-3
activation in a dose-dependent manner 1 8•20• However, the components of CS responsible
were not elucidated.
PAHs have been shown by others to activate JNKs and p-38; however upstream
signal transduction mechanisms have not been determined 18 • Since oxidized LDLs have
· been shown to be involved in EC apoptosis by a mechanism that involves AA and JNK, it
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is possible that PAHs act in a similar fashion 1 • The purpose ofthis study was to test the
hypothesis that PAHs induce EC apoptosis by a mechanism that involves PLAi-mediated
activation ofJNK.s, p-38, and caspases -8, -9, and -3. The following PAHs were studied,
1-methylanthracene (1-MA), 2-methylanthracene (2-MA), anthracene (AN), fluorene
(FL), 1-methylfluorene (1-MF), 2-methylfluorene (2-MF), phenanthrene (PA), and
fluoranthene (FA). From previous studies, AN and 2-MA were shown to be inactive 1 1 •
These compounds were used as negative controls.

MATERIALS AND METHODS
Materials

All PAHs were obtained from Aldrich (Milwaukee, WI). Methylarachidonoyl
fluorophosphonate (MAFP), a Group IV and VI PLA2 inhibitor, was obtained from
Biomol (Plymouth Meeting, PA). Anti-PARP antibody, anti-caspases-3, -8, and -9, anti
cleaved caspase-3 and CHAPS cell extract buffer and were obtained from Cell Signaling
(Beverly, MA). Anti-phospho-p-38, anti-p-38, anti-c-Jun, and anti-phospho-c-Jun (anti
p-c-Jun) antibodies were obtained from Santa Cruze (Santa Cruz, CA). The cell death elisa
plus

apoptosis kit was obtained from Roche (Indianapolis, IN). The caspase inhibitor Z-

VAD-FMK (carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]- fluoromethylketone), and
SB203580 [4-(4 '-Fluorophenyl)-2-(4' -methylsulfinylphenyl)-5-(4' -pyridyl) imidazole] , a
p-38 inhibitor, were purchased from Promega (Madison, WI). JNK inhibitor I (L form)
was obtained from Calbiochem (San Diego, California).
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Methods

Cell culture
HCAEC were obtained from Clonetics (San Diego, CA) and were maintained in
microvascular EC growth medium (Clonetics, San Diego, CA) at 37° C in 5% CO2/95%
02 • The cells were identified as EC based on morphology and staining for factor VIII
antigen. Cells were grown to 80% confluency in petri dishes and treated with PAHs 1MA, 2-MA, AN, FL, 1-MF, 2-MF, PA, FA, or vehicle for various times (Figure 12). The
cells were used between passage 4 and 7 for all the experiments.
Determination of JNK-1 and -2 activation induced by PAHs
Phosphorylation ofJNK-1 and -2 was measured in cellular lysates from PAH-, or
vehicle-treated cells in the presence and absence ofthe PLA2 inhibitor, MAFP (10 µM)
and the JNK inhibitor, JNKI (L form) (1 µM). The activation and phosphorylation of
JNK-1 and -2 were determined by Western blotting. After treatment for 90 min, plates
were washed twice in cold phosphate buffer saline (PBS) and lysed with 1 50 µl ice-cold
RIPA buffer containing 50 mM Tris, 150 mM NaCl, I% SDS, 0.5% sodium
deoxycholate, I mM DTT, 100 µM p-4-(2-aminoethyl)-benzenesulfonyl fluoride, 1 µM
pepstatin, I 00 µM leupeptin, and a phosphatase inhibitor (Sodium Orthovanadate). The
lysates were centrifuged at 10,000 g for 20 min and the supernatant subjected to 12%
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred onto nitrocellulose
membranes. The membranes were probed with antibodies against JNK-1 , -2, and
phospho-JNK-1 and -2. Bands were visualized by enhanced chemiluminescence
2

See all figures in appendix
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(Amersham Pharmacia Biotech). Cells were pretreated with inhibitors 30 min prior to
PAH treatment, cell lysates were collected and Western blotting performed.
Determination ofp-38 activation induced by PAHs
Activation and phosphorylation ofp-38 was detected by Western blotting in PAH-, or
vehicle (DMSO)-treated cells in the presence and absence of the PLA2 inhibitor, MAFP
(1 0 µM) or the p-38 inhibitor, SB203580 (1 µM), to determine the involvement of this
enzyme in P AH-induced apoptosis in HCAEC. Cells were treated with inhibitors for 30
min and then treated with PAHs for 90 min. The cells were lysed and Western blotting
performed.
Phosphorylation of c-jun induced by PAHs
Phosphorylation of c-jun was evaluated in lysates ofEC after treatment with P AHs in the
presence and absence of the PLA2 inhibitor (1 0 µM), MAFP, the inhibitor of JNK-1 and
-2 (1 µM), JNK I (L form), and SB203580 (1 µM), the inhibitor ofp-38. Cells were
pretreated with inhibitors for 30 min and then treated with PAHs for 90 min. Then, the
cells lysed and the Western blotting performed.
Caspase activation induced by PAHs
Activation of caspases including caspases -8, -9, and .:.3 has been shown to play an
important role in apoptosis "induced by fatty acids such as AA 17 • Caspases exist in the
cell as proenzymes that are activated by cleavage. The effects ofPAHs on caspase
activation were determined using Western blotting with antibodies against cleaved
caspases and procaspases. Caspase activation was assessed in cells exposed to PAHs for
2 hrs. To determine the role ofPLA2 isoforms in caspase-3 activation, Western blotting
for caspase-3 was measured in PAR-treated cells in the presence and absence of the PLA2
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inhibitor, MAFP, the caspase inhibitor (20 µM), Z-VAD-FMK, and the p-38 inhibitor,
SB203580. Western analysis was performed as described above using a 1 X CHAPS cell
extract buffer for cell lysis, and protein lysates subjected to 14 % polyacrylamide gel
electrophoresis. CHAPS cell extract buffer contains 50 mM Pipes/KOH (pH 6.5), 2 mM
EDTA, 0.1% CHAPS, 20 mg/ml Leupeptin, 10 mg/ml Pepstatin A, 10 mg/ml Aprotinin,
and 5mM DTT.
Apoptosis induced by P AHs
Two methods were used to measure apoptosis caused by P AHs: Western blotting for the
cleavage product of poly-ADP-ribose polymerase (PARP) and ELISA for detection of
histone fragmentation.
P ARP cleavage was determined after treatment with P AHs or vehicle for 8 hr.
Plates were washed twice with cold PBS and lysed in 150 µl ice-cold RIP A buffer
containing 6 M urea. Cells were lysed by sonication on ice for 10 s, 40% duty and
lysates centrifuged at 10,000 g for 20 min to remove cell debris. Protein lysates (40 µg)
were subjected to 8% SDS-PAGE. Cells were pretreated for 30 min with the PLA2
i_nhi bitor, MAFP, the p-38 inhibitor, SB203580, the JNK inhibitor, JNK I (L form), or
vehicle and then treated with PAHs for 8 hrs, and Western blotting done.
Cellular DNA fragmentation ELISA
Apoptosis was also evaluated fluorimetrically utilizing the Cell death elisa plus kit for
detecting histone fragmentation. Cells seeded into 6-well plates were treated at 80-90%
confluency with 30 µM PAHs or vehicle for 3 hrs. Histone fragmentation was evaluated
in cells treated with all eight P AHs in the presence and absence of the PLA2 inhibitor
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MAFP, the caspase inhibitor, Z-VAD-FMK, the p-38 inhibitor, SB203580, the JNK
inhibitor, JNK I (L form), or vehicle. Cells were then washed with warm PBS, lysed and
incubated with antihistone-biotin and anti-DNA-POD at room temperature for 2 hrs.
After washing with incubation buffer, 100 µl of substrate solution was added to develop
the color and measurements made at 405 nm. Additional preliminary experiments were
performed to ensure that neither the PAHs nor the inhibitors interfered with this
fluorescent assay.
Statistical analysis
Data are expressed as mean ± SEM. Data were analyzed by analysis of variance, and
group means were compared using Student-Newman-Keuls'. Test appropriate
transformations were performed on all data that did not follow a normal distribution (e.g.,
percent data). In addition, when variances are not equal or if transformation failed to
normalize the data, nonparametric statistics (Mann-Whitney rank sum test) were used.
For all studies, the criterion for statistical significance was p<0.05.

RESULTS
JNK activation and phosphorylation

Phosphorylation of JNK-1 and -2, was seen after 90 min of treatment with different
active PAHs at 30 µM concentration. Only PAHs that activated the PLA2/AA pathway
caused JNK.-1 and JNK.-2 phosphorylation. Phosphorylation was detected after treatment
with the active compounds, 1-MA, 1-MF, 2-MF, FA, FL, and PA, but not with the
inactive compounds, 2-MA, AN, or control (Figure 2 A). PAR-induced JNK-1 and -2
phosphorylation was inhibited significantly by MAFP (Figure 2 B). The JNK.-1 and -2
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inhibitor (JNK I (L form), inhibited significantly the phosphorylation of JNK-1 and -2
(Figure 2 C).
PAR-induced phosphorylation of p-38 was seen after 90 min of treatment with
different active PAHs at 30 µM concentration (Figure 3 A). No evidence of
phosphorylation was detected after treatment with 2-MA, AN, or control. MAFP and
SB203580 inhibited phosphorylation of p-38 (Figure 3 B, C).
PAH-induced phosphorylation of c-jun

c-jun is a transcription factor that is phosphorylated by p-38 and JNK-1 and -2 14 • To
evaluate PAR-induced c-jun phosphorylation, Western blotting for phospho-c-Jun was
performed in the presence and absence of MAFP, JNK I (L) form, and SB203580. Both
MAFP and JNK I (L form) decreased phosphorylation of c-jun ( Figure 4 B, C); however,
SB203580 was without effect (Figure 4 D).
Caspase-3, -8, and -9 activation induced by PAHs

We determined caspase-3, -8, and -9 activity by detection of the cleavage form of these
enzymes, after 2 hrs of treatment with different PAHs. Only the PAHs that activated the
PLA2/AA pathway caused caspase cleavage (Figure 5). Moreover, caspase-3 cleavage
was inhibited significantly by MAFP and Z-VAD-FMK (Figure 6 B, C), but not by
SB203580 (Figure 6 D).
Induction of apoptosis by PAHs in HCAEC

Apoptosis of EC induced by PAHs was evaluated by Western blotting for PARP
cleavage. In addition, to measure the degree of apoptosis quantitatively, histone
fragmentation was performed. Six out of nine compounds induced significant apoptosis
as determined by Western blot analysis for the cleavage product of PARP (Figure 7 A).
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1-MA, 1-MF, 2-MF, FL, FA, and PA, compo�ds that activated the PLA2/AA pathway,
also induced apoptosis. The two compounds, AN and 2-MA, as well as the control, that
did not cause 3H-AA release, did not induce apoptosis. Furthermore, PAR-induced
apoptosis was inhibited by MAPP at a dose that inhibited PLA2 activity (see Part II)
(Figure 7 B). The JNK inhibitor, JNK I (L form), also significantly attenuated PAH
induced PARP cleavage (Figure 7 C); however, SB203580, the p-38 inhibitor, did not
(Figure 7 D).
1-MA, FA, 1-MF, 2-MF, FL, and PA induced histone fragmentation in HCAEC,
however, there was no significant difference between AN and 2-MA when compared to
control (Figure 8). Apoptosis in response to 1-MA, FL, 1-MF, 2-MF, FA, and PA was
significantly inhibited by MAPP (Figure 9). Pretreatment with Z-VAD-FMK also
inhibited PAR-induced histone fragmentation (Figure 10); however SB203580 did not
alter this response (Figure 10). As can be seen in Figure 11, the JNK inhibitor, JNK I (L
form), significantly inhibited PAH-induced apoptosis at a concentration that effectively
inhibits c-jun phosphorylation.

DISCUSSION

PAHs, are important toxic constituents of CS and of environmental pollution. Numerous
studies have implicated them in atherosclerotic vascular disease20 ; however, little is
known about the specific cellular mechanisms of this effect. We demonstrated in
previous studies that PAHs induce apoptosis of HCAEC an event important in the
pathogenesis of atherosclerosis. Furthermore, we have demonstrated that the signal
transduction pathway involves PLA2-mediated release of AA and other fatty acids.
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In the present study we demonstrated that PAHs present in high concentrations in
CS and in urban pollution induce phosphorylation of JNK- 1 , JNK-2, p-38, and the
transcription factor c-jun. This effect was inhibited significantly by MAFP, an inhibitor
of Group IV and VI PLA2 isoforms, suggesting a role for PLAi -mediated fatty acid
release in phosphorylation of stress-activated kinases and c-jun. Inhibition of JNK-1 and
JNK-2 activation with a peptide that acts by binding to the phosphorylation site and thus
blocking phosphorylation (JNK- 1 ; L domain) significantly inhibited c-jun
phosphorylation, cleavage of caspase-8, -9, and -3 and subsequent apoptosis. These
results provide compelling evidence that PAHs induce apoptosis by a mechanism that
involves fatty acid-induced phosphorylation of JNK- 1 and JNK-2. Exposure to PAHs
also induced phosphorylation of p-38 by a PLAi-mediated mechanism. Evidence for this
is provided by the fact that PAR-induced phosphorylation was inhibited by MAFP.
Interestingly, p-38 phosphorylation did not participate in the mechanism by which PAHs
induce apoptosis since the p-38 inhibitor, SB203580, at a concentration that significantly
attenuated p-38 phosphorylation, did not attenuate c-jun phosphorylation, caspase
activation, or apoptosis. Although others have reported that PAHs induce JNK
phosphorylation 1 8 , to our knowledge this is the first report of a role for JNK
phosphorylation in PAH-mediated apoptosis.
This study also made the link between the discrete structure of these P AHs and
their activity. 1 -MA, I -MF, 2-MF, FL, FA, and PA, that have bay- and/or bay-like
regions (Figure 1 ) caused AA release, JNK. and c-jun phosphorylation, caspase cleavage,
and apoptosis of HCAEC. On the other hand, AN and 2-MA, which are linear structures
did not have any of these effects.
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Previous studies suggest that AA and other fatty acids can induce JNK and p-38
phosphorylation in a time- and concentration-dependent manner2 1 • AA and linoleic acid
activate JNK through activation of NADPH oxidase, an enzyme that is responsible for
production of superoxide anion 17•22 • This finding was supported by the fact that
superoxide anion generation parallel JNK. activation induced by various fatty acids.
Moreover, AA-induced JNK activation can be blocked by antioxidant treatment2 1 • PAHs
likely also induce JNK activation by a similar mechanism, since they have been shown to
induce cellular oxidative stress23 • NADPH oxidase exists in its active form as a complex
of several proteins and cofactors. AA induces a conformation is required to achieve
proper assembly of the protein complex. PAHs may also act by facilitating the
association of the protein complex with the membrane, since they have similar lipophility
to AA. Future studies will focus on the role of oxidative stress on PAH-induced EC
apoptosis.
Apoptotic stimuli generate signals that are either transmitted across the plasma
membrane to intracellular regulatory molecules or addressed directly to targets present
within the cell. An example of the former mechanism is the Fas/Fas ligand/Fas
associated death domain (FADD) pathway . . Binding of Fas ligand to Fas recruits the
death domain protein, FADD, which is required for caspase-8 activation and subsequent
initiation of lethal proteolytic cascades. FADD couples the Fas death receptor to
procaspase-8, subsequent oligomerization promotes procaspase-8 autoactivation 19•24-28 •
· In the current study, we provide strong evidence that PAHs act in this way (i.e., by
inducing JNK. phosphorylation and subsequent caspase activation). The latter mechanism
involves the regulation of mitochondrial function by the BCL-2 family of proteins.
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Release of cytochrome c from the mitochondria is a proapoptotic signal. Proapoptotic
protease activating factor (Apaf-1) is activated upon biding with cytochrome c after its
release from the mitochondria. The antiapoptotic Bcl-2 proteins downregulate apoptosis
by either preventing cytochrome c release directly, or by sequestering Apaf-125. There is
also a reciprocal regulation f Bcl-2 by cytochrome c. Apoptotic signals can block Bcl-2
function, which in turn causes mitochondrial membrane depolarization and subsequent
cytochrome c release, proteolytic activation of procaspase-9 and subsequent activation of
caspase-3 and other lethal proteolytic cascades25.
In the present study, we provide convincing evidence that PAHs act by activating
the intracellular regulatory protein FADD. We did not, however, rule out additional
mechanisms of PAH-induced apoptosis. PAHs may cause release of cytochrome c by a
direct effect or indirectly by inhibiting Bcl-2. All active compounds tested, but not the
inactive compounds, caused poly(ADP-ribose) polymerase (PARP) cleavage to its
inactive form. This cleavage was inhibited with PLA2 and JNK-1 and -2 inhibitors but
not with a p-38 inhibitor. These data provide evidence for the involvement of the
PLA2/AA pathway as well as JNK-1 and -2, but not p-38, in PAH-induced PARP
cleavage. These results were confirmed using another measure of apoptosis,. histone
fragmentation. The cleavage of PARP is mediated by caspase-3. Cleavage of PARP by
caspase-3, causes production of cleavage products that cannot repair DNA damage, thus,
PARP cannot prevent caspase-induced cleavage of intemucleosomal DNA 1 8 . Caspase-3
is an effector caspase that has a short prodomain and mediates apoptosis by destruction of
cellular contents and activation of the machinery that degrades DNA 15· 1 8. Caspase-3 is
responsible for dissolution of the nucleus ( chromatin condensation and DNA
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fragmentation) and cleavage ofthe cytoskeletal and nuclear matrix proteins. Caspase-3
also causes intemucleosomal cleavage ofDNA. PARP plays a crucial role in DNA repair
as well as replication, transcription, and cell death.
Many studies have investigated the role ofCS in vascular cell injury. In one
study 20 Chinese passive smokers that had been exposed to tobacco smoke > 8 hrs a day
for 2 to 24 years, were shown to have impaired endothelial production and bioavaliability
ofnitric oxide (NO), enhanced platelet aggregation, coronary artery spasm, and a
pathological lipid profile20 . Wang and his colleagues showed that CS induces EC
apoptosis, in a dose dependant-manner by a caspase-3 mediated mechanism. They
concluded that EC apoptosis likely contributes to and initiates atherosclerosis 1 8 . In
another study, they demonstrated that acute CS exposure was associated with increase in
oxidative stress, mitochondrial dysfunction, and cytochrome c release in macrophages.
This effect is likely important in the light of the fact that macrophages play an important
role in EC injury during atherosclerosis 1 8 • Our results confirm and extend the results of
Wang and colleagues. They showed that CS induces apoptosis by a caspase-3-mediated
mechanism, but they did not identify components of CS responsible for this effect. Our
study provides strong evidence that the PAHs we studied may be responsible, at least in
part, for this effect.
Six of the PAHs were active in inducing apoptosis but two were not. The
structural feature that the six compounds shared was the presence of one or more bay or
bay-like regions in the molecule. The inactive compounds had linear structures. This
discrete structure-activity relationship suggests that PAHs may act by binding to
receptors or other proteins in the cell. The signal transduction pathway targeted by PAHs
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is the same as that targeted by the Fas/Fas Ligand death pathway, suggesting that PAHs
may bind the Fas receptor. The role of the Fas receptor in PAH-induced apoptosis is the
subject of future investigation. The presence of a discrete structure-activity relationship
may be useful for predicting toxicity of the PAHs present in CS. Future studies will
focus on further defining this relationship.
Many studies have investigated the role of large molecular weight PAHs such as
benzo(a)pyrene and dimethyl benzanthracene in atherosclerosis29 • However, this is the
first report of a potential role for small molecular weight PAHs. The small molecular
weight PAHs are significantly more water-soluble than large molecular weight
compounds, as a result, they are more bioavaliable. One study showed that 95% of 1 4C
phenanthrene was absorbed into the arterial system of pigs after oral administration while
only 33% of benzo(a)pyrene reached the circulation30 • The presence of these compounds
. in high concentration in CS and urban pollution in addition to the effectiveness of their
absorption into the circulation lends credence to the possibility that they are important in
the progression of atherosclerotic vascular disease.

SUMMARY

PAHs are important toxic constituents of CS and of environmental pollution. Numerous
studies have implicated them in atherosclerotic vascular disease20 • Our results
demonstrate that PAHs present in high concentrations in CS and in urban pollution
induce phosphorylation of JNK- 1, JNK-2, p-38, and the transcription factor c-jun. This
effect is inhibited significantly by MAFP,.an inhibitor of Group IV and VI PLA2
isoforms, suggesting a role for PLAi-mediated fatty acid release in phosphorylation of
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stress-activated kinases and c-jun. We also found that pretreatment with JNK-1 and -2
inhibitor (JNK-1 L form) significantly inhibits c-jun phosphorylation, cleavage of
caspase-3 and subsequent apoptosis (PARP cleavage and histone fragmentation). These
results provide compelling evidence that P AHs induce apoptosis by a mechanism that
involves fatty acid-induced phosphorylation of JNK-1 and JNK-2. Furthermore, p-38
phosphorylation did not participate in the mechanism by which PAHs induce apoptosis as
the p-38 inhibitor, SB203580, at a concentration that significantly attenuate p-38
phosphorylation, did not attenuate c- jun phosphorylation, caspase activation, or
apoptosis. This study also establishes a link between the discrete structure of these P AHs
and their activity. The presence of bay- and/or bay-like regions in some compounds
causes AA release, JNK and c-jun phosphorylation, caspase cleavage, and apoptosis of
EC. Oq. the other hand linear structures did not have any of these effects. This discrete
structure-activity relationship suggests that PAHs may act by binding to receptors or
other proteins in the cell. Future studies will be focused on further identifying this
relationship.
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1 -m ethylanthracene

A n thracene

6 1 0-4 8 -0

1 2 0 - 1 2-7
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Figure 1: Structures of polycyclic aromatic hydrocarbons. Antrhracene (AN) and 2methylanthracene (2-MA) are linear structures. 1-metheylanthracene (1-MA) and 1methylfluorene ( 1-MF) have bay-like region formed by methyl group. Fluqrene (FL), 2methylfluorene (2-MF), fluoranthene (FA), and phenantherene (PA) have bay-region.
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Figure 2. PAR-induced phosphorylation of JNK- 1 and JNK-2. Cells were exposed to
PAHs for 90 min with or without the PLA2 inhibitor, MAFP, ( 1 0 µM), or the JNK
inhibitor, JNK I (L form) (1 µM). Cells were pretreated with inhibitors for 30 min prior
to treatment with PAHs (30 µM), cell lysed, and JNK- 1 and -2 phosphorylation
determined by immunoblotting with an antibody against phospho-JNK-1 and -2. Panel A
shows phosphorylation of JNK-1 and -2 after treatment with FL, FA, 2-MF, 1 -MA, PA,
and 1 -MF but not AN, 2-MA, or vehicle. JNK phosphorylation was inhibited by MAFP
(panel B) and by the JNK inhibitor, JNK I (L form) (panel C). n=3.
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Figure 3. PAH-induced phosphorylation of p-38. Cells were exposed to PAHs for 90 min
with or without the PLA2 inhibitor, MAFP (10 µM) or the p-3 8 inhibitor, SB203580 (1
µM). Cells were pretreated with inhibitors for 30 min prior to treatment with PAHs (30
µM), cells lysed and p-3 8 phosphorylation determined by immunoblotting with an
antibody against phospho-p-3 8 (pp-38). Panel A shows phosphorylation of p-38 after
treatment with FL, FA, 2-MF, 1-MA, PA, and 1-MF but not AN, 2-MA, or vehicle. p-38
phosphorylation was inhibited by MAFP (panel B) and to lesser extent by SB2035 80
(panel C). n=3.
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Figure 4. PAH-induced phosphorylation ofc-jun. Cells were exposed to PAHs for 90
min with or without the PLA2 inhibitor, MAFP (1 0 µM), the p�38 inhibitor, SB203580 (1
µM), or the inhibitor of JNK-1 and-2, JNK I (L form), (1 µM). Cells were pretreated
with inhibitors for 30 min prior to treatment with PAHs (30 µM), lysed, and c-Jun
phosphorylation determined by immunoblotting with an antibody against phospho-c-jun
(p-c-jun). Panel A shows a increase in phosphorylation ofc-jun after treatment with FL,
FA, 2-MF, 1-MA, PA, and 1 -MF, when compared to control. No such increase was
observed with AN or 2-MA. c-Jun phosphorylation was inhibited by MAFP (panel B),
JNK inhibitor (panel C), and to lesser extent by SB203580 (panel D). n=3.
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Figure 5. Cleavage of caspases-3, -8, and -9 induced by PAHs. HCAEC were treated
with different PAHs (30 µM) for 2 hrs, and total proteins were isolated. Equal amounts of
proteins (40.0 µg) were subjected to immunoblot analysis as described in Materials and
Methods. Panel A, B, and C show the cleavage of caspases (50 kD proactive enzyme, 36
kD intermediate inactive form or 16 kD active form) and activation of caspases-3, 8, and
9, respectively. n=3.
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Figure 7. Apoptosis of human coronary artery endothelial cells induced by different
PAHs, PARP cleavage. Cells were exposed to PAHs for 8 hrs with or without the PLA2
inhibitor, MAFP (10 µM) the p-38 inhibitor, SB203580 (1 µM), or the inhibitor of JNK-1
and -2, JNK I (L form). Apoptosis was determined by detection of PARP cleavage
product (inactive form, ,.., 85 kD) as described in Materials and Methods. Panel A shows
PARP cleavage caused by PAHs, 1-MA, FL, 1-MF, 2-MF, FA, and PA but not with 2MA, AN, or vehicle. PARP cleavage was inhibited by MAFP (panel B), and JNK I (L)
form (panel C) but not by SB203580 (panel D). n=3.
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Figure 8. Apoptosis of human coronary artery endothelial cells induced by different
PAHs, histone fragmentation. Cells were exposed to P AHs for 3 hrs. Apoptosis
determined by detection of histone fragmentation as described in Materials and Methods.
1 -MA, FL, 1 -MF, 2-MF, FA, and PA caused significant histone fragmentation.
However, 2-MA, AN, or vehicle did not cause histone fragmentation. *Significantly
different from vehicle-treated control; p< 0.05. n=3.
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Figure 10. Inhibition of apoptosis of human coronary artery endothelial cells induced by
the caspase inhibitor, Z-VAD-FMK (20 µM) but not the p-38 inhibitor, SB203580 (1
µM). Cells were pretreated for 30 min with inhibit�r prior to treatment with 30 µM I 
MA, FL, 1-MF, 2-MF, FA, PA, or vehicle for 3 hrs and apoptosis determined by
detection of histone fragmentation as described in Materials and Methods. Z-VAD-FMK ·
caused significant inhibition of histone fragmentation; however, SB203580 did not.
*Significantly different from vehicle-treated control; # Significantly different from PAH
treated EC in the absence of inhibitor; n=3.
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Figure 1 1 . Inhibition of apoptosis of human coronary artery endothelial cells induced by
the JNK I inhibitor, JNK I (L form) ( 1 µM). Cells were pretreated for 30 min with
inhibitor prior treated with 30 µM 1 -MA, FL, I -MF, 2-MF, FA, PA, or vehicle for 3 hrs
and apoptosis determined by detection of histone fragmentation as described in Materials
and Methods. Inhibition of JNK- 1 and -2 induced significant inhibition of histone
fragmentation. *Significantly different from vehicle-treated control; # Significantly
different from EC treated with PAHs in the absence of inhibitor p<0.05 ; n=3.
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PART IV: · Identification and Characterization of Phospholipase A2
isoforms targeted by Polycyclic Aromatic Hydrocarbons in Vascular
Smooth Muscle Cells
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INTRODUCTION

Atherosclerotic vascular diseases are the major sequelae of smoking in adults and of
passive exposure to tobacco smoke in non-smokers1 . Cigarette smoking (CS) causes
endothelial cells (EC) dysfunction, mononuclear cells infiltration, cholesterol deposition,
platelet aggregation, smooth muscle proliferation, and plaque rupture2 • Acute coronary
thrombosis resulting from rupture of an atherosclerotic plaque accounts for
approximately 50% ofdeaths due to myocardial infarction. Vascular smooth muscle
cells (SMC) are responsible for production of interstitial collagen that is important for
maintenance oftensile strength ofthe fibrous plaque3'4 • Recent studies indicate that SMC
apoptosis is a major contributing factor to plaque rupture, and subsequent myocardial
infarction1 •3 • When these cells die, the loss ofcollagen formation results in decrease
tensile strength ofthe plaque, which ultimately leads to plaque rupture3 • CS significantly
increases the incidence of plaque rupture and subsequent acute coronary thrombosis.
Moreover, vascular biopsies from smokers demonstrate significantly more SMC
apoptotic cell death when compared to biopsies from nonsmokers. Similar results have
been shown in vitro, after exposure of human vascular cells to CS extract, but the
causative components in CS responsible for this effect have not been identified1 •5 .
Several key processes that occur during atherosclerosis involve arachidonic acid
(AA) and its metabolites6 • The AA pathway has been implicated in EC
dysfunction/death, platelet and inflammatory cell activation, and alteration of SMC
growth and differentiation. The mechanism by which this pathway promotes
atherogenesis involves second messenger functions ofAA and its metabolites. AA is
released from membrane phospholipids by the action ofa variety of intracellular
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phospholipases; including phospholipases C, D, and A2 • The majority of free AA is
derived from the activity ofphospholipases A2 (PLA2), which cleave AA directly from
the sn-2 position of membrane phospholipids7•

8

•

Over ten different families ofPLA2 have been characterized to date. These
enzymes are classified according to whether their active site contains a serine or a
histidine residue9 • In general, low molecular weight secreted isoforms (Groups I, II, III,
V, IX, and X) have a histidine at the active site; whereas the high molecular weight
intracellular enzymes (Groups IV and VI) as well as low molecular weight (Group VII
and VIII PLA2s) have an active site serine. Of the Groups IV and VI, several isoforms
have been identified9- 1 1 •
Three enzymes have been characterized from Group IV. These include a
calcium-dependent PLA2 (Group IV cPLA2) that is arachidonoyl-selective and plays an
essential role in eicosanoid biosynthesis 1

0

•

It is regulated by phosphorylation and

requires calcium in order to bind to the nuclear membrane during activation9•

10

.

More

recently, two new members of this family have been identified. These are designated as
Group IVf3 and 1Vy 12 . Group IVf3 is a 114 kD cytosolic protein that is calcium-dependent
with a broad substrate specificity i.e., it will cleave several different fatty acids from the
sn-2 position. Group IVy is a 61 kD membrane bound protein that has a stricter substrate

specificity i.e. it will cleave other fatty acids from the membrane but it prefers to interact
with palmitic or AA. This enzyme has sequential lysophospholipase activity as well9- 1 3 •
After cleaving the sn-2 fatty acid it will cleave the fatty acid from the sn- 1 position.
Several inhibitors have been developed that target these three enzymes. In general, these
inhibitors are analogues ofAA and act by competing with substrate for enzyme binding.
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These include methylarachidonoyl fluorophosphonate (MAFP) and trimethylfluoro
ketone (AACOCF3) 11 • Since these inhibitors act by binding the active site serine, they
are also effective inhibitors of Group VI enzymes11 .
Three isoforms have been characterized from the Group VI family. The first to be
identified was the Group VIa enzyme found in cardiac muscle. This enzyme is a 40 kD
calcium-independent, arachidonoyl-selective enzyme that prefers plasmenylcholine
phospholipids9· 11. Group VIJ3, of which two splice variants have been identified, is an
85-88 kD membrane bound protein that is arachidonoyl nonselective and calcium
independent9-12. These enzymes are specifically inhibited by bromoenol lactone (BEL), a
suicide substrate that irreversibly binds the active site of the enzyme 11 •
Several laboratories have reported the involvement of group IVa cPLA2 and VIJ3
iPLA2 in apoptotic signal transduction pathways7, 13-13. Past reports indicate that Group
IVa is involved in tumor necrosis factor-a (TNF-a) -induced apoptosis. Cells from
Group !Va-knock-out mice are resistant to the effects of TNF-a1 8 ; however, Fas/FasL
has been shown to be equally effective in mediating apoptosis in Group IVa positive and
negative cell lines13 • These data suggest that this enzyme is not a critical mediator of
Fas/FasL-induced apoptosis.
Several studies have implicated Group Vlf3 in apoptotic cell death caused by the
Fas/Fas-associated death domain (FADD) pathway6• 17• Upon activation of Fas, Group
VIJ3 causes release of fatty acids that induce phosphorylation of stress-activated kinases
(i.e., c-jun-N-terminal kinases and p-38). These kinases cause downstream activation of
transcription factors and caspases. Moreover, there is a positive feedback loop identified,
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wherein fatty acid-induced caspase activation causes reciprocal VI� cleavage. The
cleaved product exhibits a 2- to 3-fold increase in PLA2 activity, thus further driving the
process ofapoptosis6 •
We have demonstrated recently that polycyclic aromatic hydrocarbons (PAHs)
present in the tar fraction ofCS and in environmental pollution induce apoptosis ofhuman
coronary artery EC (HCAEC) by a mechanism that involves activation and increased
expression ofat least 2 isoforms ofPLA2 1 7. Substituted and unsubstituted fluorene
compounds activate only the Group IVy enzyme. Fluorene-induced activation of this enzyme
is essential for the mechanism by which these P AHs induce EC apoptosis. In contrast, P AHs
such as 1-methylanthracene, fluoranthene, or phenanthrene induced apoptosis by activating
both Group IVy and Group VI�. Furthermore, discrete structural determinants were required
for activation ofPLA2 and apoptosis. Linear compounds were inactive, whereas compounds
containing bay- or bay-like regions increased the expression and activation of the two PLA2
isoforms listed above 1 7 • We have also demonstrated that PAR-induced apoptosis of EC
involves a pathway similar to the Fas/FADD pathway in that it involves PLAi-mediated
phosphorylation of JNK-1 and-2 and subsequent activation of caspases -8, -9, and -3.
Since SMC apoptosis is also a significant event in the pathogenesis of atherosclerosis,
experiments were performed to investigate the effects ofP AHs on SMC in vitro and to
characterize the roles of different PLA2 isoforms in this effect. In addition, we evaluated the
effects ofPAHs on F ADD expression to investigate whether PAHs interact with this
pathway. The following PAHs were examined: 1-methylanthracene (1-MA), triphenylene
(TRI), phenanthrene (PA), fluoranthene (FA), 1-methylfluorene (1-MF), 2,3 benzofluorene
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(2,3 BF) anthracene (AN), and chrysene (CH) (Figure 13 ). These compounds were chosen
because they are found in high concentrations in the environment and in tobacco smoke and
are among the 16 EPA priority PAHs because of their toxic potential.

MATERIALS AND METHODS
Materials

All PAHs were obtained from Aldrich (Milwaukee, WI) [5-6,8-9, 1 1- 12, 14-15-3 H].
Arachidonic acid {3 H-AA; 200-240 Ci/mmol) and phosphatidylcholine, L-a.-1-palmitoyl2-arachidonoyl-[ arachidonoyl-1-1 4 C]

(

14

C-AA) were purchased from American

Radiolabeled Chemicals (St. Louis, MO). L-a.-phosphatidylcholine, P-arachidonoyl-v
palmitoyl (C:20:4, [cis]-5,8,11, 14/C: 16) (PC-AA) and L-a.-phosphatidylcholine,

p

linoleoyl-v-palmitoyl (C 18:2, [cis]-9,12/C 16:0) (PC-LA) were obtained from Sigma
Aldrich (St. Louis, MO). L-3-phosphatidylcholine, 1-palmitoyl-2-[2- 1 4C]linoleoyl ( 14 C
LA) was purchased from Amersham Pharmacia Biotech (Piscataway, NJ). Bromoenol
lactone (BEL), a Group VI PLA2 inhibitor, and methylarachidonoyl fluorophosphonate
(MAFP), a Group IV and VI PLA2 inhibitor, were obtained from Biomol (Plymouth
Meeting, PA). Cell death elisa plus apoptosis kit was obtained from Roche (Indianapolis,
IN). Antibodies for poly-ADP-ribose polymerase (PARP), caspase-3, and CHAPS cell
extract buffer were obtained from Cell Signaling (Beverly, MA). Anti-F ADD and anti-p
FADD were obtained from Santa Cruze (Santa Cruz, CA).

3

See all figures in appendix
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Methods

Cell culture
Human aortic smooth muscle cells (SMC) were obtained from Clonetics (San Diego,
CA). Cells were cultured in smooth muscle cell growth medium-2 supplemented with
5% fetal bovine serum (FBS), 2 ng/mL human basic fibroblast growth factor, 0.5 ng/mL
human epidermal growth factor, 50 µg/mL gentamicin, 50 µg/mL amphotericin-B, and 5
µg/mL bovine insulin. For all experiments, early passage cells were grown to 80-90%
confluence and made quiescent by serum starvation (0.1 % FBS) for at least 24 hrs.
Determination of PAH-induced fatty acid release from prelabeled cells
To determine the effect of various PAHs on fatty acid release, cells were seeded into 6well culture plates at a density of 3Xl 05 cells/well and grown to 75% confluency. Cells
were prelabeled with 0.25 µCi/ml of 3 H-arachidonic acid {3H-AA) (specific activity=180240 Ci/mM;) for 24 hrs 17 • To determine total cellular uptake of 3H-AA, the cells at 8090% confluency were washed twice with Hanks' balanced salt solution (HBSS) and
equilibrated for 45 min in HBSS + 0.1% bovine serum albumin (BSA) to inhibit
reacylation and metabolism of released 3H-AA. Radiolabeled cells were exposed to
various concentrations (1-40 µM) of 1-MA, 1-MF, PA, FA, AN, TRI, 2,3 BF, CH, or
vehicle, for 1 hr. Cumulative release of 3H-AA into the medium was measured by
scintillation counting and expressed as percent of total cellular radioactivity.
Characterization of PLA2 isoforms
Release of 3H-AA into the medium was determined in cells treated with PAHs, with and
without the Group IV and VI specific PLA2 inhibitors, MAFP and BEL. Cells were
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preincubated for 30 min with MAFP (1 0 µM) or BEL (7 .5 µM) before the treatment with
PAHs (30 µM) or vehicle (DMSO). 3H-AA release was determined as described above.
Characterization of PLA2 isoforms present in SMC was determined by cell-free PLA2
assays, reverse-transcriptase polymerase chain reaction {RT-PCR), and Western blotting.
Cell-free PLA2 activity was measured in whole cell sonicates as described previously 1 8 •
Cells were washed in Ca2+-free PBS containing 5 mM EDTA and 1 mM PMSF,
resuspended in cold homogenizing buffer, placed on ice, and sonicated. Light
microscopy was used to verify that the cells were broken. Based on previous inhibitor
studies, experiments were designed to assay for Groups IVa, f3, y and Vlf3 enzymes.
Since Groups IVa and IVy prefer AA over linoleic acid at the sn-2 position, the
substrates 1 -palmitoyl-2- [arachidonoyl-1 - 14C] phosphatidylchline { 14C-AA-PC; 1 µM)/
unlabelled AA-PC (1 0 µM) was used to assay for their activities. Since Groups 1Vf3 and
Vlf3 are arachidonoyl-nonselective, the substrate 1 -palmitoyl-2-linoleoyl [linoleoyl-1 14

C]

phosphatidylcholine { 1 4C-LA-PC; 1 µM)/unlabeled LA-PC (1 0 µM) was used to

assay for their activities. Substrates were dried under nitrogen and resuspended by
sonication in assay buffer to a final optimum concentration as determined in preliminary
experiments. To determine the role of calcium in activation of PLA2 , assays were
performed in the presence of either 5 mM CaCli or 5 mM EGTA. To determine if PAHs
activate PLA2 enzymes by interacting directly with the proteins, cell lysates were
incubated with 1 4C-AA-PC/AA-PC or 14C-LA-PC/LA-PC for 30 min in the presence and
absence of PAHs. To determine whether PAHs activate PLA2 directly, experiments were
also- performed in the presence and absence of inhibitors (MAPP and BEL) to validate the
1 00

selectivity of inhibitors for specific isoforms. Cell-free PLA2 assays are designed to
target select isoforms and therefore, are effective means to validate the specificity of
inhibitors for select PLA2 isoforms. Reactions were terminated by addition of
chloroform-meth�ol, 2:1 (v/v), the chloroform layer extracted and spotted on silica gel
thin layer chromatography plates. The plates were chromatographed in a neutral lipid
solvent and the lipids visualized with Ii vapor. The zones corresponding to fatty acid and
phospholipid were cut out and radioactivity determined by scintillation counting.
Reverse transcription-polymerase chain reaction {RT-PCR) for PLA2 isoforms expressed
by SMC
To determine the expression of different PLA2 isoforms, RT-PCR was performed as
described previously. Total cellular RNA was isolated from SMC (10-20 x 106 cells)
using NucleoSpin nucleic acid purification kits (Clontech, Palo Alto, CA) according to
instructions of the manufacturer. RNA was isolated from SMC using guanidine
isothiocyanate-CeCl ultracentrifugation. Concentration of the RNA was determined by
absorbance at 260 nm. For the RT reaction, 2.5 µg of RQl -treated RNA, 1 µg of
oligo(dT) 12. 1 8 primers (Life Technologies, Inc., Grand Island, NY), and 10 mM dNTPs in
nuclease-free water were heated to 65 °C for 5 minutes and then placed on ice for 1 min.
To this solution 0.1 M DTT, 40 units of RNase OUT (recombinant RNase inhibitor), and
10 X buffer (100 mM Tris-HCI [pH 8.31), 500 mM KCl, and 25 mM MgCh) were added
in a final volume of 20 µ1. The reaction mixture was incubated at 42 ° C for 2 min, 200
units of M-ML V reverse transcriptase was added and incubated for 42 °C for 90 min, and
the reaction was terminated at 70 °C for 15 min then placed on ice. A negative control
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reaction was performed without the M-MLV. Four sets of downstream and upstream
primers for PLA2 Group IVa.,

p, y, and Group Vlfl have been synthesized previously and

were used in the PCR reaction. Primers used for PCR were: PLA2 group IV a. (sense, 5'
CCAAATGTCATITATAGATCC-3 '); PLA2 group IVa. (antisense, 5'
CATGAACTATGCTTTGGGTITAC-3'); PLA2 group IV(} (sense, 5'
ACTGAGTGCCCTGCCCTCTGGTCAAG-3 '); PLA2 group IV(} (antisense, 5'
TGCCCATAAAGAACTCGGAGCCAAAGA-3 '); PLA2 group IVy (sense, 5 '
AGAAAGAAGAAAAGGCGGCCGTGGAGAGAC-3 '); PLA2 group IVy (antisense, 5 '
CGGCACTGAAGTCGAAGGAGAGGATGAGGT-3 '); PLA2 group Vlfl (sense, 5 ' 
ATGCAGTTCTITGGCCGCCTGGTCAAT-3 '); PLA2 group VI(} (antisense, 5 ' 
TGATGATCATCTCCGCACACCCCTTCTG-3 '). PCR reactions were performed using
TAQ polymerase, products recovered and a portion analyzed by 1 .5 % agarose gel
electrophoresis to determine the size.
Westem blot analysis for PLA2 isoforms
After treatment with 30 µM of 1-MA, 1 -MF, FA, TRI, PA, CH, AN, 2,3BF, or vehicle,
cells were washed with cold PBS and then lysed in RIPA buffer (50 mM Tris, 1 50 mM NaCl, 1 % SDS, 0.5% sodium deoxycholate, 1 mM DTT, 1 00 µM p-4-(2-aminoethyl)
benzenesulfonyl fluoride, 1 µM pepstatin, 1 00 µM leupeptin, and sodium orthovanadate).
The lysates were centrifuged at 10,000 g for 20 min and the protein concentrations
determined. Equal concentrations of protein were subjected to 8% or 10% SDS- _
polyacrylamide gel electrophoresis (SOS-PAGE) and transferred onto nitrocellulose
membranes. The membranes were probed with antibodies against Group IVa. PLA2 , VIP
1 02

PLA2 , and IVy PLA2 (a gift from Dr. Christina Leslie). Bands were visualized by
enhanced chemiluminescence (Amersham Pharamacia Biotech).
Overexpression of PLA2 isoforms in SMC
Characterization of PLA2 isoforms, targeted by specific PAHs, was further verified by
transiently overexpressing PLA2 isoforms in SMC. A full-length cDNA encoding the
human PLA2 Group IVy (accession number XM_009 1 1 9), and PLA2 group VIJ3
(accession number XM_039248) was generated using a template obtained from SMC via
RT-PCR. The cDNAs were ligated into a PCR 3.1 vector (Invitrogen) of the TA cloning
system for subcloning and sequencing. PCR3. l expression vectors containing PLA2
cDNAs were transfected into cells using the Superfect transfection method (Qiagen).
Positive clones were selected, and clones with the highest expression levels were
identified by Western blotting and used for transfection. Wild type SMC and SMC
overexpressing either group IVy or group Via were pre-labeled with 3H-AA for 24 hrs
and exposed to I -MA, FA, TRI, PA, or vehicle for 1 hr. Release of 3H-AA into the
medium was measured and results expressed as fold change in activity (3H-AA release
from overexpressing cells/ 3H-AA release from wild type).
Measurement/analysis of apoptosis induced by PAHs
Westem blot analysis for the cleavage product of PARP and caspase-3 was used to
measure apoptosis. In addition, FADD phosphorylation was determined.
The activation and phosphorylation of FADD was analyzed by Western blotting.
After treatment for 2 hrs with PAHs or vehicle, plates were washed twice in cold PBS
and lysed with 1 50 µl ice-cold RIPA buffer. The lysates were centrifuged at 1 0,000 g for
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20 min and the supematants were subjected to 12% SDS-PAGE and transferred onto
nitrocellulose membranes. The membranes were probed with antibodies against F ADD
and phospho-F ADD. Bands were visualized by enhanced chemiluminescence.
The effects of PAHs on caspase-3 activation were determined using Western
blotting using antibodies against cleaved (active) caspases and procaspases. Caspase-3
activation was assessed in cells exposed to PAHs for 3 hrs. Cells were lysed in CHAPS
(50 mM Pipes/KOH (pH 6.5), 2 mM EDTA, 0.1% Chaps, 20 mg/ml Leupeptin, 10 mg/ml
Pepstatin A, 10 mg/ml Aprotinin, 5 mM DTT), and protein lysates subjected to 14 %
- SDS-PAGE.
For detection of PARP cleavage, cells were treated with different PAHs for 6, 8,
and 12 hrs. ·cells were washed twice with cold PBS and lysed in 100 µl ice-cold RIPA
buffer containing 6 M urea. Cells were lysed by sonication on ice for 2 times at 30%
duty and lysates were centrifuged at 10,000 g for 20 min to remove cell debris. Protein
lysates were subjected to 8% SDS-PAGE.
Statistical analysis
Data are expressed as mean ± SEM. The data were analyzed by analysis of variance
(ANOVA), and group means were compared using Student-Newman-Keuls'. Test
appropriate transformations were performed on all data that did not follow a normal
distribution (e.g., percent data). In addition, when variances are not equal or if
transformation failed to normalize the data, nonparametric statistics (Mann- Whitney rank
sum test) were used. For all studies, the criterion for statistical significance was p<0.05.
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RESULTS
PAHs cause PLA� activation and 3B-AA release

Little 3 H-AA release was observed from unstimulated SMC (DMSO control group) or
from cells exposed to the inactive PAH, AN; however, 1-MA, caused significant,
concentration-dependent release of 3 H-AA (Figure 2A). TRI, PA, FA, but not CH,
caused significant, concentration-dependent release of 3 H-AA (Figure 2 B). FA and I 
MF caused significant 3 H-AA release; however, the response to 2,3-BF was not different
from the vehicle-treated groups (Figure 2C). Pre-treatment with MAFP ( 1 0 µM), an
inhibitor of group IV and VI PLA2 isoforms, attenuated approximately 60% of the 3 H-AA
release from cells treated with 1-MA, 1 -MF, FA, PA, and TRI; whereas pretreatment
with BEL (7 .5 µM), an inhibitor of Group VI PLA2 isoforms induced approximately 20%
inhibition in response to all PAHs (Figure 3).
SMC demonstrate calcium-dependent and -independent PLA� activity

To characterize further the PLA2 isoforms functioning in SMC, cell-free assays were
performed. Cell-free PLA2 assays were performed using 14 C-PC-AA/PC-AA or 14 C-PC
LA/ PC-LA as substrates in the absence of calcium. SMC displayed significant PLA2
activity against both PC-AA and PC-LA, however, the activity-against PC-AA was
greater. When PC-AA was used as a substrate the response was inhibited by MAFP but
not BEL. However, when PC-LA was used as the substrate, both BEL and MAFP
inhibited the effect (Figure 4). These data suggest the presence of Group IVy and VIJ3
PLA2 isoforms in SMC.
SMC exhibited significant PLA2 activity in the presence of calcium using both
PC- 14 C-AA and PC- 14C-LA as substrates, however, the response was greater with PC1 05
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C-AA than with PC- 14C-LA, suggesting that SMC contain PLA2 isoforms that are

calcium-dependent, and either arachidonoyl selective/arachidonoyl non-selective. This
calcium-dependent activity was inhibited in the presence of MAFP but not BEL (Figure
5) suggesting that these cells demonstrate significant Group IVa and/or IVP PLA2
activity.
Treatment of cell lysates with different PAHs did not enhance PLA2 activity
(Figure 6). PLA2 activity assayed on lysates treated with the active P AHs for 30 min.
These data suggesting that PAHs might activate different PLA2 isoforms through
membrane bound receptors.
SMC express Group IVa, B, y, and Group VIB

RT-PCR and Western analysis using PAR-treated SMC was performed to detect the
expression of different PLA2 isoforms. mRNA and protein expression for both calcium
independent and calcium-dependent enzymes was demonstrated by RT-PCR and Western
analysis (Figure 7). SMC constitutively express group IV a,

p, y, and VIP PLA2.

Since the results of the cell-free assays, RT-PCR and Western analysis suggested that the
SMC express all 4 isoforms of PLA2 , experiments were performed to evaluate whether
incubation with PAHs would result in upregulation of these isoforms. Western blot
analysis was performed using lysates from 2, 4, and 6 hrs-treated cells. 1 -MA, 1 -MF, FA
and PA, but not TRI, AN, 2,3BF, CH, or vehicle caused a significant increase in
expression of group VIP, IVa, and IVP (Figure 8). Figure 9 shows the increase in
expression of Group Vly PLA2 after 4 hrs treatment with different PAHs. 1-MA, PA, 1 -
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MF, and FA caused increase in expression of Vly PLA2 , however TRI, AN, CH, and 2,3
BF did not differ from control.
PLA2 overexpression increased 3H-AA release in SMC

Since the expression of PLA2 Groups VIJ3 and IVy were the most increased by treatment
with PAHs, these proteins were overexpressed in SMC. Western analysis of the
overexpressed cells were performed before conducting 3H-AA release experiments to
ensure the increase expression. Figure 10 shows that both isoforms were increased in
expression upon transfection. Group IVy and VIJ3 overexpression caused significant
increase in 3H-AA release when compared to wild type cells upon exposure to PAHs
(Figure 1 1 ).
PAHs caused apoptosis in SMC

The ability of different PAHs to phosphorylate F ADD was further determined. The SMC
were treated with PAHs (30 µM) for 2 hrs, and total proteins were isolated. Equal
amounts of proteins (40-60 µg) were subjected to immunoblot analysis (Figure 1 2). All
active compounds, 1-MA, PA, I -MF, FA, and TRI were able to activate and
phosphorylate F ADD but not the inactive compounds or the vehicle.
We evaluated caspase cleavage after 2, 4, and 6 hr of treatment with different
PAHs. All five compounds (I -MA, I -MF, FA, TRI, and PA) that activate the PLA2/AA
pathway and caused 3H-AA release were able to activate caspase-3 (Figure 13) at 30 µM
concentration after 6 hrs treatment. Whereas, 2,3BF, CH, AN, or vehicle, inactive
compounds, did not cleave caspase-3. No evidence of caspase-3 cleavage was observed
after 2 or 4 hr treatment with PAHs.
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Five out of eight compounds induced significant apoptosis as determined by
Western analysis for the cleavage product of PARP (Figure 14). I -MA, I -MF, TRI, FA,
and PA, compounds that activated PLA2, also induced apoptosis. The three compounds,
AN, CH, and 2,3BF, as well as the control that did not cause 3 H-AA release, did not
induce apoptosis. Cleavage was only detected after 8 hrs of treatment with I -MA and FA
treated groups. The rest of the active compounds demonstrated PARP cleavage after 12
hrs of treatment.

DISCUSSION

This study is the first to provide strong evidence for the involvement of PAHs, which are
present in high concentrations in CS as well as in industrial pollutants, in activation of the
PLA2/AA pathway and subsequent apoptosis of SMC. Five of the 8 compounds tested
caused 3H-AA release in a concentration-dependent fashion. The 5 active compounds
also induced apoptosis at a concentration that induced significant 3 H-AA release. The
onset of 3 H-AA release proceed the onset of apoptosis by several hours. These results
suggest a role for alteration in gene expression. In addition, specific PLA2 inhibitors that
are selective for Group IV and VI enzymes inhibited 3 H-AA release and attenuated the
apoptotic effect suggest that PAHs induce SMC apoptosis by a mechanism that involves
PLA2.
The data suggest that activation of PLA2 and induction of apoptosis by PAHs
requires discrete structural features. The major differences between 1-MA, 2-MA, and
AN are that I-MA is a compound that contains a bay-like region on the molecule,
whereas 2-MA and AN are linear compounds (Figure 1). These results are consistent
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with previous studies by others that have demonstrated that bay- and bay-like regions are
required for PAR-induced activation of c-jun-N-terminal kinase 1 9 • The results with CH;
however, was inconsistent with this hypothesis since this compound has bay regions but
was inactive. One possibility for this is that this compound is significantly bulkier than
the other active compounds with bay- or bay-like regions. The existence of a discrete
structural determinant for activity suggests that these compounds interact with a protein
or proteins in the cell. Whether a ligand binds to a protein can depend on the size of the
ligand. A large molecule may be too bulky to bind the active site of the protein, whereas
a smaller molecule can. Another possible explanation for these results is that CH is
significantly less water-soluble (0.002 mg/L) than the active compounds FA (0.26 mg/L)
and PA (1 .6 mg/L). However, solubility cannot explain all the results. If so, it would be
expected that a direct relationship would exist between water solubility and PLA2
activation and this was not the case. For example, FA was significantly more active than
PA in activating PLA2 and inducing apoptosis, but it was an order of magnitude less
soluble than PA. Thus, it is likely that both molecular structure and solubility play
important roles in the effects of PAHs on SMC cells PLA2 activation and apoptosis.
Results from cell-free PLA2 assays suggested that SMC display significant PLA2
activity against both PC-AA and PC-LA. The activity against PC-AA was greater in the
presence than in absence of calcium, suggesting that SMC have significant calciwn
dependent and -independent activities. Furthermore, the activity against PC-AA was
significantly greater than that against PC-LA. These data indicate that SMC have both
arachidonoyl-selective and arachidonoyl non-selective PLA2 isoforms. The results with
RT-PCR and Western blotting confirm the results. The activity against PC-AA in the
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presence of calcium was inhibited with MAFP but not BEL, excluding the po_ssibility that
this assay was measuring group VI enzyme activity. The most likely PLA2s responsible
for AA release under these conditions are Group IVP (a 1 1 4 kD protein) or Group IVa
(85 kD). The cells also demonstrate Group VI(3 (85-88 kD protein). Under calcium-free
condition, when PC-AA was used as a substrate the response was inhibited by MAFP but
not BEL. However, when PC-LA was used as the substrate, both BEL and MAFP
inhibited the effect. These data suggest the presence of Group IVy (calcium-independent,
and inhibited by MAFP), and VI(3 (calcium-independent, and inhibited by MAFP and
BEL) PLA2 isoforms in SMC.
Treatment of the lysates directly with PAHs did not cause any increase in PLA2
activity, suggesting that these compounds do not interact directly with PLA2 enzymes. It
is possible that they act on the membrane by interacting with a receptor or with other
downstream signaling protein in the cell. Indeed, a likely candidate is F ADD and the
active PAHs were shown to induce phosphorylation of this protein.
Since the results of the cell-free assays, RT-PCR, and Western analysis suggested
that the SMC express all 4 isoforms of PLA2 , Western blotting for the PAR-treated SMC
for long term (6 hrs), caused significant induction of Group IVa,

p, y, and VI(3 PLA2 •

1-

MA, PA, FA, 1 -MA, and TRI, and to a lesser extent the inactive linear compounds,
caused significant increase in expression of all four enzymes after 6 hrs of treatment. The
data suggest that PAHs might cause upregulation to different PLA2 isoforms that may be
responsible for PAH-induced apoptosis of SMC.
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Since inhibitor studies cannot definitively determine the specific PLA2s that are
activated by select compounds, SMC were transfected with PLA2 isoforms that were the
most strongly expressed by SMC after PAH treatment (Group IVy and Group Vlf3).
Westem analysis for the overexpressed cells was performed to verify an increase in the
expression of the protein in the overexpressed cells. Cells that overexpressd Group IVy
and Vlf3 PLA2 release significantly more 3 H-AA when stimulated with 1 -MA, FA, TRI,
and PA when compared to wild type cells. In addition, cells overexpressing these
enzymes were significantly more prone to apoptosis. The data suggest that both of these
enzymes are responsible for P AH-induced AA release and subsequent apoptosis. We
cannot, however, exclude the possibility that Group IVa and f3 are also involved in this
effect since these enzymes are also targeted by MAFP. This possibility requires further
investigation.
SMC play an important role in the maintenance of fibrous plaque strength since
they produce interstitial collagen that provides plaque tensile strength20. Activation of
medial SMC that migrate into the intima to proliferate and produce extracellular matrix
proteins is the key event in atherosclerosis2 1 . Recent studies provide compelling
evidence that SMC apoptosis is an important mechanism of SMC loss, reduction of
plaque tensile strength, and subsequent plaque rupture during atherosclerosis and acute
myocardial infarction22 . SMC are responsible for the production of interstitial collagen
that is necessary for plaque stability. SMC apoptosis has been demonstrated in
specimens from atherosclerotic and restenotic lesions of patients2 1 ,23 • In an in vitro study
by Bennett and his colleagues, more apoptotic cells were observed in proliferating SMC
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than non-proliferating SMC24 • Another study showed a higher incidence of apoptosis in
specimens from injured arteries in ballooned rat, mouse carotid, and rabbit iliac arteries
than shown control. This apoptosis was demonstrated within 30 min, peaking after 7-1 5
d and disappearing after re-endothelialization2 1 • Thus, SMC apoptosis is considered to be
a rapid process after injury. Similar studies have been reported in other animal models
and reviewed2 1 '23,25 • An increase in SMC apoptosis has also been demonstrated in
cholesterol-fed rabbits and hyperlipidemic knockout mice 2 1 • Furthermore, SMC cultured
from atherosclerotic coronary lesions proliferate more slowly and undergo higher rates of
apoptosis than SMC cultured from normal blood vessels. Thus several studies suggest
that SMC proliferation is important for plaque stability and increase in SMC apoptosis is
important in plaque instability. Since smooth muscle cell loss/injury is known to be
important in the process of coronary artery disease and atherosclerotic disease involving
other arteries as well, induction of SMC apoptosis by cigarette components may represent
an important mechanism of smoking-induced augmentation of cardiovascular diseases.

SUMMARY

We investigated the effect of 8 different PAHs on SMC PLA2 activation and induction of
apoptosis. Our data show that five of the 8 compounds tested cause 3 H-AA release in a
concentration-dependent fashion. The 5 active compounds also induce apoptosis at a
concentration that induce significant 3 H-AA release. In addition, specific PLA2 inhibitors
that are selective for Group IV and VI enzymes inhibit 3H-AA release and attenuate' the
apoptotic effect, suggesting that PAHs induce SMC apoptosis by a mechanism that
involves PLA2. The data suggest that both discrete structure and solubility of PAHs play
1 12

an important role activation of PLA2 and induction of apoptosis in SMC. Results from
cell-free PLA2 activity assays, RT-PCR, and Western blotting show that SMC express 4
isoforms of PLA2, Group IVa.,

13, y, and Group VIJ3 PLA2.

Western blotting for the long

term PAR-treated SMC (6 hrs), shows significant induction of all four enzymes, which
suggests that PAHs may cause up-regulation to different PLA2 isoforms that may be
responsible for PAR-induced apoptosis of SMC. Transfection of SMC PLA2 isoforms
that are the most strongly expressed (Group IVy and Group VIJ3 ) cause a significant
increase in 3H-AA when stimulated with active PAHs as compared to wild type cells.
Our data suggest that both of these enzymes are responsible for PAH-induced AA release
and subsequent apoptosis in SMC. Further investigation is required to test the possibility
of Group IV a. and J3 involvement in this effect.
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1 -m ethylanth rac ene

A n th ra c e n e

6 1 0 -4 8 -0
CH 3

1 -m e t h y l fl u o re n e

P h e n a n t h re n e
8 5 -0 I - 8

1 7 3 0 -3 7 -6

F l u o r a n th e n e

T riphenylene

2 0 6 - 4 4 -0

2 1 7 -5 9 -4

2,3-benzofluorene

C h rysene

92-24-0

2 I 8-0 1 -9

Figure 1 : Structures of polycyclic aromatic hydrocarbons. Antrhracene (AN) has linear
structures. 1 -metheylanthracene (1 -MA) and 1 -methylfluorene ( 1 -MF) have bay-like
region formed by methyl group. Triphenylene (TRI), fluoranthene (FA), chrysene (CH),
and phenantherene (PA) have bay-region. 2,3-benzofluorene (2,3 BF) has a truncated
structure.
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Figure 2. 3 H-arachidonic acid {3 H-AA) release from human aortic smooth muscle cells.
Figure 2 A shows 3H-AA release induced by 1 -methylanthracene (1 -MA), but not by
anthracene (AN). Cells were prelabeled with 3 H-AA and stimulated for 1 h with vehicle
or various concentrations of 1-MA or AN as described in Materials and Methods.
Cumulative release of 3 H-AA into the medium was measured by scintillation counting.
*Significantly different from vehicle-treated control; n=6.
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Figure 2. Continued. Figure 2 B shows 3 H-arachidonic acid {3H-AA) release from human
aortic smooth muscle cells induced by triphenllene (TRI) and phenanthrene (PA), but
not chrysene (CH). Cells were prelabeled with H-AA and stimulated for 1 hour with
various concentrations of FA, PA, CS or vehicle as described in Materials and Methods.
Cumulative release of 3H-AA into the medium was measured by scintillation counting.
*Significantly different from vehicle-treated control; n=6.
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Figure 2. Continued. Figure 2 C shows 3H-arachidonic acid (3H-AA) release from human
aortic smooth muscle cells induced by 1 -methylfluorene (1 -MF) and fluoranthene (FA),
but not with 2,3-benzofluorene (2,3-BF). Cells were prelabeled with 3H-AA and
stimulated for 1 h with various concentrations of 1 -MF, FA, 2,3-BF, or vehicle as
described in Materials and Methods. Cumulative release of 3H-AA into the medium was
measured by scintillation counting. *Significantly different from vehicle-treated control;
n=6.
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Figure 3. Inhibition of PAH-induced 3H-AA release by MAFP and BEL in smooth
muscle cells (SMC). Pretreatment with MAFP (10 µM) or BEL (7.5 µM) for 30 min
prior to treatment with different PAHs attenuated significantly 3H-AA release. The
figure shows % inhibition caused by MAFP (10 µM) or BEL (7.5 µM). MAFP
attenuated 3H-AA release by � 60% in 1-MA, FA, and PA-treated cells, while it caused <
60% inhibition in 1-MF and TRI-treated cells. BEL induced approximately 20%
inhibition in response to all PAHs. * denotes a statistically significant difference between
control and treated groups (p < 0.05). n=6.
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Figure 4. SMC demonstrate significant Group IVy and VIP PLA2 activity. Cell-free
PLA2 assays were performed using 14C-PC-AA/PC-AA or 14C-PC-LA/ PC-LA as
substrates in the absence of calcium. Lysate from SMC displayed significant PLA2
activity against both PC-AA and PC-LA, however, the activity against PC-AA was
greater. When PC-AA was used as a substrate the response was inhibited by MAFP but
not BEL. However, when PC-LA was used as the substrate, both BEL and MAFP
inhibited the effect. * denotes a statistically significant difference in PLA2 activity. #,
denotes a statistically significant difference between control and treated groups
(p < 0.05).
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Figure 5. SMC demonstrate significant Group IVa and/or IVP PLA2 activity. Cell-free
PLA2 assays were performed using 14 C-PC-AA/PC-AA or 14C-PC-LA/ PC-LA as
substrates in the presence of calcium. Significant PLA2 activity was seen against PC-AA
and PC-LA, however, the activity against PC-AA was greater. MAFP, but not BEL,
significantly inhibited PLA2 activity when PC-AA and PC-LA used as substrates. *,
denotes a statistically significant difference in PLA2 activity. #, denotes a statistically
significant difference between control and treated groups (p < 0.05).
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Figure 6. PAHs do not directly activate Groups IVy or VIJ3 PLA2 isoforms. Calcium
independent cell free assays for Group IVy or VIJ3 were performed after treatment of cell
lysates with 30 µM of PAHs or vehicle for 30 min. Exposure of lysates to 1 -MA, 1 -MF,
PA, TRI, or vehicle did not alter activity of either enzyme. *, denotes a statistically
significant difference between blank and protein (p < 0.05).
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Figure 7. SMC express 4 different PLA2 isoforms: mRNA and protein expression for
both calcium-dependent and calcium-independent enzymes were demonstrated by RT
PCR and Western blotting. SMC constitutively express the Group VI J3 and Group
IVa., J3, and y isoforms. n=3. Left panel shows Western blot analysis for Group N a, J3,
y, and VI J3 PLA2 , while the right panel shows mRNA expression for different PLA2
isoforms.
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Figure 8. PAR-induced upregulation of different PLA2 isofonns. The effect of treatment
of different PAHs on the expression of group VI f3 PLA2 (left panels A, B, and C) shows
the effect of treatment after 2, 4, or 6 hrs respectively. Only FA and 1 -MA increased
expression of Group VI f3 PLA2 after 4 hrs. However, after 6 hrs of treatment, all
compounds increased protein expression, albeit, inactive compounds were less effective.
Right panel A, B and C shows the difference in expression of group IVa and f3 PLA2
isoforms after 2, 4 and 6 hr of treatment. No changes in expression of IV a (85 kD) were
seen at 2 and 4 hrs, and only a slight increase in expression was seen at 6 hrs. However,
expression of IV a was significantly increased after treatment with 1 -MA and FA after 4
hrs and by all compounds (both active and inactive) by 6 hrs. A slight increase in VIf3
expression was also seen at 6 hrs. n=3 .
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6l kD

Figure 9. PAR-induced upregulation ofGroup IVy PLA2 isoforms. The effect of
treatment of different PAHs on the expression ofGroup IVy PLA2. The panel shows the
effect oftreatment after 4 hrs. FA, PA, 1-MF, and 1-MA increased expression ofGroup
IVy PLA2 ; however, inactive compounds did not change expression.
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Figure 10. Western analysis of SMC overexpressing Group IVy and VIJ3 PLA2 • Cells
were transfected with Gp IVy or VIJ3 and the lysates were collected as described
previously. 8 % and 12% gels were run and the membranes were blotted using antibodies
against different PLA2 isoforms. Panel A. shows increase in expression of group IVy
compared to the wild type. Panel B shows increase in expression of group VIJ3 compared
to the wild type.
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Figure 1 1. Overexpression of lVy or VIJ3 PLA2 isoforms increases 3H-AA release in
response to PAHs. Wild type SMC and SMC overexpressing either Group IVy or
Group VIJ3 were prelabeled with 3H-AA for 24 hrs then exposed to different PAHs or
vehicle for 1 hr. Release of 3H-AA into the medium was measured and the results were
expressed as fold change in activity. Significant increases in activity for both isoforms
were observed after treatments with 1-MA, FA, TRI, and PA. *, denotes a statistically
significant difference between control and treated groups (p < 0.05).
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Figure 12. Expression of FADD. The SMC were treated with PAHs (30 µM) for 3 hrs,
and total proteins were isolated. Equal am_ounts of protein (40-60 µg) were subjected to
immunoblot analysis. The figure shows FADD phosphorylation with 1-MA, 1-MF, FA,
.TRI, and PA but not with AN, CH, 2,3-BF or the control group. n=3.
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Figure 1 3. Cleavage of caspase-3 induced by PAHs. SMC were treated with different
PAHs (30 µM) for 2 hrs (panel A), 4 hrs (panel B) or 6 hrs (panel C), and total proteins
isolated. Equal amounts of proteins ( 40.0 µg) were subjected to immunoblot analysis as
described in Materials and Methods. No evidence of caspase-3 cleavage was detected
after 2 or 4 hrs of treatment. After 6 hrs of treatment all of the active compounds (1-MA,
1-MF, TRI, FA, and PA) activated caspase-3 while the inactive compounds as well as the
vehicle control did not. n=3.
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Figure 1 4. Apoptosis of SMC induced by different PAHs. Cells were exposed to 30 µM
1 -MA, AN, 1 -MF, TRI, FA, PA, 2,3BF, CH, or vehicle for'·6 (panel A), 8 (panel B) or 12
hrs (panel C) and apoptosis determined by detection of PARP cleavage (~ 85 kD) as
described in Materials and Methods. n=3. Only I -MA and FA showed PARP cleavage at
8hrs. While all active compounds induced PARP cleavage by 12 hrs. No 85 kD
fragment was detected from cells treated with AN, 2,3 BF, or CH at any time. n=3
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